



Investigational therapies such as inhaled vasoactive intestinal peptide are showing early signs of promise, said Dr. Bernhard Burian.

### COPD New-Drug Pipeline Is Beginning to Flow

BY BRUCE JANCIN Elsevier Global Medical News


SALT LAKE CITY — Old hands at managing chronic obstructive pulmonary disease using the traditional menu—limited largely to bronchodilators, corticosteroids, oxygen, immunization, and advice to quit smoking—may be stunned to learn that the COPD drug development pipeline is now filled to an unprecedented degree.

The procession of potential new agents is arriving just in time. It is estimated that COPD will be the third-leading cause of death worldwide by the year 2020.

The first wave of new products to reach pharmacy shelves will be improved versions of existing drugs rather than totally new drug classes. Earlier along in the development process are entirely new and promising drug classes addressing novel potential pathophysiologic targets in COPD, Dr. Stephen C. Lazarus said at a satellite symposium sponsored by Sepracor and held in conjunction with the annual meeting of the American College of Chest Physicians.

Fixed-dose combination therapy has been amply shown to be more effective than either agent alone at reducing COPD exacerbations and improving lung function; the increased drug cost is more than offset by the benefits. Formoterol and tiotropium is a combination close to gaining marketing approval. Formoterol

See Pipeline • page 9



Source: Centers for Medicare and Medicaid Services

### Bronchoscopic Innovations Show Potential for COPD

#### Procedures target lung volume reduction.

#### BY BRUCE JANCIN Elsevier Global Medical News

SALT LAKE CITY — Pulmonologists are developing a variety of innovative bronchoscopic procedures to achieve nonsurgical lung volume reduction as treatment for advanced emphysema—and hoping to reinvent their specialty along the way.

The goal is to capitalize upon the functional and mortality benefits documented with lung volume reduction (LVR) surgery in a subset of participants in the NIH-sponsored National Emphysema Treatment Trial—but without the associated hefty perioperative mortality, major morbidity, and expense.

If the bronchoscopic innovations prove successful, they could transform the field of respiratory medicine, much as percutaneous angioplasty and stenting have revolutionized cardiology, speakers predicted at the annual meeting of the American College of Chest Physicians. Planning is underway for large multicenter randomized trials of novel investigational bronchoscopic LVR procedures that have successfully passed the pilot study phase of development. Among them are insertion of one-way valves into pockets of diseased lung tissue, biologic tissue destruction with induction of scarring, and stent placement to create decompression of hyperinflated diseased lungs.

"I have this dream that you'll go into the recovery room and you'll be sweating with scrubs on and the cardiologist is going to come in and say, 'Wow, I had a tough case—I put three stents in,' and you'll say, 'Well, I had a tougher one—I put in seven valves,' or 'put in six stents.' Maybe we'll be able to induce physiologic changes and gain time for these patients," said Dr. Bartolome Celli, FCCP, professor of medicine at Tufts University, Boston.

Dr. Daniel H. Sterman, FCCP,

See Bronchoscopic • page 8

#### I N S I D E

Critical Care Medicine Sepsis Surprise Statins and angiotensin-II receptor blockers may cut mortality in sepsis. • 7

#### Pulmonary Medicine Heat and Treat

Bronchial thermoplasty significantly reduced asthma exacerbations. • 9

#### Pulmonary Perspectives Postthrombotic Syndrome

Relatively little is known about venous thromboembolic disease's most common sequela. • 14



Cardiothoracic Surgery Cut to Video Video-assisted thorascopic

surgery may cause less morbidity for patients undergoing lobectomy. • 22

### **RF** Ablation Promising in Lung Cancer

#### BY BRUCE JANCIN Elsevier Global Medical News

ROME — Two-year cancer-specific survival following percutaneous radiofrequency ablation of inoperable non-small-cell lung cancer was 92% in a multinational pilot study, Dr. Riccardo Lencioni reported at the annual meeting of the Cardiovascular and Interventional Radiological Society of Europe.

"That's impressive. It's better than what's currently quoted for radiation therapy," observed Dr. Lencioni, professor of radiology at the University of Pisa (Italy).

Based upon these results from the Radiofrequency Ablation of Pulmonary Tumors Response Evaluation (RAPTURE) trial, planning is underway for a definitive, randomized controlled trial, he added. Lung cancer is the No. 1 cause of cancer mortality, accounting for more than 160,000 deaths per year in the United States. At present, the only reliably effective treatment is surgical resection, with a 5-year survival rate of 70%. Unfortunately, 70%-85% of lung cancer patients have unresectable tumors or are inoperable because of comorbid disease. This has been the driving force behind interest in percutaneous

CHEST PHYSICIAN 5635 Fishers Lane, Suite 6000 Rockville, MD 20852 CHANGE SERVICE REQUESTED radiofrequency ablation (RFA).

RAPTURE is an ongoing, single-arm prospective study involving RFA performed under conscious sedation with CT guidance in 106 patients with 186 biopsy-proven lung cancer tumors up to 3.5 cm in size. None of the participants was a surgical candidate. Of the 106 patients, 33 presented with

#### See RF Ablation • page 2



### Statins May Slow Decline of **Lung Function in Smokers**

Drug therapy cuts hospital visits by COPD patients.

BY BRUCE JANCIN Elsevier Global Medical News

SALT LAKE CITY — Statin therapy may slow the decline in lung function in smokers and exsmokers with chronic lung disease, Dr. Walid G. Younis said at the annual meeting of the American College of Chest Physicians.

This preliminary finding from a retrospective observational study raises the intriguing possibility that statins might be able to slow the progression of chronic obstructive pulmonary disease (COPD) or restrictive lung disease in smokers and former smokers, noted Dr. Younis of the University of Oklahoma, Oklahoma City.

He reported on 182 current and 303 ex-smokers, mean age 66 years, who were

#### IN THIS ISSUE

#### News From the College • 10

**Critical Care Commentary** The incidence of severe status asthmaticus requiring pediatric ICU admission appears to be increasing. • 16

#### **CHEST PHYSICIAN IS ONLINE**

CHEST PHYSICIAN is available on the Web at www.chestnet.org/ about/publications.

AMERICAN COLLEGE OF CHEST PHYSICIANS

President Mark J. Rosen, M.D., FCCP

**Executive Vice President and CEO** 

Pamela L. Goorsky

Copy Editor Christine Mentink

Editorial Assistant Arren M. Graf

Alvin Lever, MA, FCCP (Hon)

Editor in Chief Susan M. Harding, M.D., FCCP

Vice President, Publications Stephen J. Welch

Assistant Vice President, Editorial Resources

Р

AMERICAN COLLEGE OF

C H E SH Y S I C I A N S

EDITORIAL ADVISORY BOARD

Michael H. Baumann, M.D., M.S., FCCP, Mississippi

Thomas R. Behrenbeck, M.D., Ph.D., FCCP, Minnesota Robert J. Cerfolio, M.D., FCCP, Alabama

Vera A. De Palo, M.D., FCCP, Rhode Island LeRoy M. Graham, M.D., FCCP, Georgia Jeffrey W. Hawkins, M.D., FCCP, Alabama

Peter McKeown, M.B.B.S., FCCP, North Carolina Aymarah M. Robles, M.D., FCCP,

(Deputy Editor, Pulmonary Perspectives) Florida

George A. Sarosi, M.D., FCCP, Indiana Paul A. Selecky, M.D., FCCP, California

Curtis N. Sessler, M.D., FCCP, Virginia Deborah Shure, M.D., Master FCCP,

(Editor, Pulmonary Perspectives) Florida

Gerard A. Silvestri, M.D., FCCP, South Carolina

E-mail: chestphysiciannews@chestnet.org



The most likely mechanism of statin therapy's benefits involves anti-inflammatory effects. **DR. YOUNIS** 

being followed at the Oklahoma City Veterans Hospital. Half were on statin therapy-predominantly simvastatin-for primary or secondary cardiovascular pre-

vention. A total of 319 patients had COPD, 99 patients had restrictive fibrotic lung disease, and the rest had normal lung function.

The mean baseline forced expiratory volume in 1 second  $(FEV_1)$  was 57% of the predicted value. During nearly 3 years of follow-up, FEV<sub>1</sub> declined by 88 mL/year in patients not on a statin but by only 12 mL/year in those who were. Moreover, forced vital capacity fell by 125 mL/year in patients not on a statin while actually increasing by 22 mL/year in those on statin therapy. Equally robust benefits

were noted in statin users regardless of whether they were current or ex-smokers. The rate of respiratory-related hospi-

talizations and emergency department visits during the study period was 35% lower in COPD patients on a statin. However, statin therapy had no impact on rates in patients with restrictive lung disease.

The most likely mechanism of statin therapy's benefits on lung function involves anti-inflammatory effects. Statins decrease blood levels of inflammatory cytokines, including interleukin-6 and -8 and tumor necrosis factor– $\alpha$ , which are known to be involved in the pathogenesis of COPD, Dr. Younis said.

"I think this is provocative enough that you should think seriously about doing a well-designed randomized prospective trial," commented Dr. Ronald F. Grossman, FCCP, professor of medicine at the University of Toronto. 

### **RAPTURE Study Results Analyzed**

**RF Ablation** • from page 1

We started this

trial with patients

who truly had no

other treatment

options. This was

last-resort therapy.'

DR. LENCIONI

non-small-cell lung cancer (NSCLC), 53 had metastases of colorectal cancer (CRC) to the lung, and 20 had lung metastases from other sites.

Two-year overall survival was 48% among patients with NSCLC and 62% in those with CRC metastases. "Of course, these figures may not look so exciting,'

Dr. Lencioni conceded. "But remember, we started this trial with patients who truly had no other treatment options. This was last-resort therapy."

Moreover, most of the NSCLC patients were longtime smokers and they had high mortality rates due to cardiovascular causes and chronic obstructive pulmonary disease during followup. The 2-year cancer-specific survival-that is, freedom from cancer-related mortality-was far more impressive at 92% in the NSCLC group and 82% in patients with CRC metastases, he continued.

In terms of the technical procedural success of RFA. Dr. Lencioni noted that 93% of treated tumors showed no regrowth at the 3-month follow-up CT.

At the 15-month follow-up, the local tumor control rate was 88%. That's higher than reported in many series involving RFA of tumors in the liver and other sites. The likely explanation is that physical energy used for thermal destruction of tissue is particularly efficient when the target is a solid tumor surrounded by air, the radiologist said.

The 30-day mortality in RAPTURE was 0%. One-quarter of patients experienced pneumothorax as a result of the procedure. There were four cases of pleural effusion requiring draining, two cases of pneumonia, and one of atelectasis.

"RAPTURE is an important study," Dr. Luigi Solbiati commented in his Andreas Gruentzig Lecture. "It shows the only significant complication of RFA for lung cancer is pneumothorax-and honestly, it's not a significant complication from a clinical point of view because only about 20% of these pneumothoraxes require aspiration and a chest tube," said Dr. Solbiati, professor of diagnostic imaging at

the University of Milan. Dr. Lencioni noted that small-scale reports of favorable experiences with RFA in lung cancer are starting to come in from centers not in-

volved in the RAPTURE study. For example, University of Pittsburgh surgeons reported that 15 of 18 treated patients were alive at 14 months' follow-up, with a mean progression-free interval of 17.6 months in the 9 patients with stage I disease (J. Thorac. Cardiovasc. Surg. 2005;129:639-44). And French investigators reported an 18-month overall

survival of 71% in 60 treated patients (Radiology 2006;240:587-96).

RAPTURE was funded by RITA Medical Systems Inc., which makes the expandable electrodes used in the study.

Dr. Gerard Silvestri, FCCP, comments: One of the vexing problems in early-stage lung cancer is facing a patient with potentially curable stage I disease and *discovering that they are medically* inoperable. The results published above are exciting but must be interpreted with caution, as the numbers are small and the long-term outcomes are uncertain. What is needed now are larger trials to confirm these findings and define the patient population that will benefit the most. Studies are needed to compare this treatment to standard therapy. Finally, these patients should be evaluated by a thoracic surgeon to assure that they cannot be offered lung-sparing surgery.



### **CHEST PHYSICIAN**

CHEST PHYSICIAN, the newspaper of the American College of Chest Physicians, provides cutting-edge reports from clinical meetings, FDA coverage, clinical trial results, expert commentary, and reporting on the business and politics of chest medicine. Each issue also provides material exclusive to the members of the American College of Chest Physicians. Content for CHEST PHYSICIAN is provided by the Elsevier Society News Group and Elsevier Global Medical News. Content for NEWS FROM THE COLLEGE is provided by the American College of Chest Physicians.

The statements and opinions expressed in CHEST PHYSICIAN do not necessarily reflect those of the American College of Chest Physicians, or of its officers, regents, members, and employees, or those of the Publisher. The American College of Chest Physicians, its officers, regents, members, and employees, and Elsevier Inc. do not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to products, drugs, or services mentioned herein.

Address Changes: Send editorial correspondence and address changes to Circulation, CHEST PHYSICIAN, 5635 Fishers Lane, Suite 6000, Rockville, MD 20852.

POSTMASTER: Send change of address (with old mailing label) to CHEST PHYSICIAN, 5635 Fishers Lane, Suite 6000, Rockville, MD 20852. CHEST PHYSICIAN (ISSN 1558-6200) is published monthly for the American College of Chest Physicians by Elsevier Inc., 60 Columbia Rd., Building B, Morristown, NJ 07960, 973-290-8200, fax 973-290-8250.

©Copyright 2006, by the American College of Chest Physicians

Director, ESNG Mark Branca Executive Director, Editorial Mary Jo M. Dales Executive Editor, IMNG Denise Fulton Executive Editor, EGMN Kathy Scarbeck Publication Editor Terry Rudd Publication Associate Editor Jav C. Cherniak VP, Medical Education Sylvia H. Reitman

**ELSEVIER SOCIETY NEWS GROUP** 

President, IMNG Alan J. Imhoff

Senior Director, Marketing and Research Janice Theobald Executive Director, Operations Jim Chicca Director, Production and Manufacturing Yvonne Evans Executive Director, Business Operations Bari Edwards Art Director Louise A. Koenig

Display Advertising Manager The Walchli Tauber Group: 443-512-8899, fax 443-512-8909. garv.walchli@wt-group.com. stephen.tauber@wt-group.com

Classified Sales Manager Robin Cryan: 800-379-8785, fax 212-633-3820, r.cryan@elsevier.com

Advertising Offices 60 Columbia Rd., Building B, Morristown, NJ 07960, 973-290-8200, fax 973-290-8250

CLASSIFIED ADVERTISING OFFICES 360 Park Ave. South, 9th Floor, New York, NY 10010, 800-379-8785

EDITORIAL OFFICES 5635 Fishers Lane, Suite 6000, Rockville, MD 20852, 240-221-4500, fax 240-221-2541



Tork.

## -NEW-THE POWER TO

#### **A NEW CLASS OF SMOKING CESSATION THERAPY**

• Unique, dual-action combination of agonist and antagonist effects at  $\alpha_4\beta_2$  nicotinic acetylcholine receptors

CHANTIX<sup>™</sup> (varenicline) is indicated as an aid to smoking cessation treatment in adults.

### Safety and efficacy of CHANTIX in combination with other smoking cessation drug therapies have not been studied.

#### Zyban is a registered trademark of Glaxo Group Limited.

**References: 1.** CHANTIX [package insert]. New York, NY: Pfizer Inc; 2006. **2.** Center for Drug Evaluation and Research. Approval package for: application number NDA 21-928: statistical review(s). Food and Drug Administration Web site. Available at: http://www.fda.gov/cder /foi/nda/2006/021928\_s000\_Chantix\_StatR.pdf. Accessed August 25, 2006. **3.** Gonzales D, Rennard SI, Nides M, et al, for the Varenicline Phase 3 Study Group. Varenicline, an  $\alpha 4\beta 2$  nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *JAMA*. 2006;296:47-55. **4.** Jorenby DE, Hays JT, Rigotti NA, et al, for the Varenicline Phase 3 Study Group. Efficacy of varenicline, an  $\alpha 4\beta 2$  nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *JAMA*. 2006;296:47-55. **4.** Jorenby DE, Hays JT, Rigotti NA, et al, for the Varenicline Phase 3 Study Group. Efficacy of varenicline, an  $\alpha 4\beta 2$  nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *JAMA*. 2006;296:56-63.

#### www.chantix.com

#### Please see brief summary of prescribing information on last page of this advertisement.

# HELP THEM OUT

#### QUIT RATES SUPERIOR TO ZYBAN<sup>®</sup> AT 12 WEEKS IN HEAD-TO-HEAD CLINICAL TRIALS (*P*=.0001)<sup>1,2\*</sup>

of subjects who received CHANTIX 1 mg bid quit smoking by the end of 12 weeks vs:

- Approximately 30% of subjects who received Zyban 150 mg bid
- Approximately 17.5% of subjects who received placebo

#### WELL-STUDIED TOLERABILITY AND SAFETY PROFILE

- The most common adverse events associated with CHANTIX were nausea, sleep disturbance, constipation, flatulence, and vomiting
- Nausea was reported by approximately 30% of subjects treated with CHANTIX 1 mg bid, with approximately a 3% discontinuation rate during 12 weeks of treatment

### GET QUIT SUPPORT PLAN

 A personalized behavioral support program developed by experts specifically for your CHANTIX patients

### **NOW, TURN MORE SMOKERS INTO QUITTERS**



\*Results from 2 identically designed, 52-week (12 weeks pharmacotherapy, 40 weeks nonpharmacotherapy follow-up), randomized, double-blind, parallel-group, multicenter clinical trials (study 4: N=1022; study 5: N=1023) in which CHANTIX 1 mg bid was compared with Zyban 150 mg bid and placebo for efficacy and safety in smoking cessation. For trial inclusion, subjects must have smoked at least 10 cigarettes per day over the past year, with no period of abstinence greater than 3 months, and must have been bupropion naive. The primary efficacy end point in both trials was the carbon monoxide (CO)–confirmed 4-week continuous abstinence rate for weeks 9 through 12, defined as the percentage of subjects who reported no smoking (not even a puff) or use of any nicotine-containing products confirmed by an exhaled CO measurement of 10 ppm or less at each clinic visit. (Studies 4 and 5 from the CHANTIX package insert.)<sup>1-4</sup>

Subjects were provided with an educational booklet on smoking cessation and received up to 10 minutes of smoking cessation counseling at each clinic visit in accordance with Agency for Healthcare Research and Quality guidelines.<sup>1</sup>

### **VTE Prophylaxis Deficient in Most At-Risk Patients**

BY BRUCE JANCIN Elsevier Global Medical News

SALT LAKE CITY — Only one-third of U.S. medical inpatients at increased risk for venous thromboembolism receive appropriate prophylaxis as recommended by American College of Chest Physicians guidelines, according to a large study.

About half of the remaining two-thirds of at-risk patients receive suboptimal venous thromboembolism (VTE) prophylaxis. The other half receives none at all,

**CHANTIX** (varenicline) tablets

re prescribing, please consult Full Prescribing Information

INDICATIONS AND USAGE CHANTIX is indicated as an aid to smoking cessation treatment.

#### PRECAUTIONS

CHAVITA is indicated as an aid to smoking cessation treatment. PRECAUTIONS General Nausea was the most common adverse event associated with CHANTX treatment. Nausea was generally described as mild or moderate and often transient; however, for some subjects, it was persistent over several months. The incidence of nausea was dose-dependent. Initial dose-titation was beneficial in reducing the occurrence of nausea. Nausea was reported by approximately 30% of patients treated with CHANTIX 1mg BID after an initial week of dose titration. In patients taking CHANTIX or mg BID, the incidence of nausea was 16% following initial tration. Approximately 30% of subjects treated with CHANTIX 1mg BID in studies involving 12 weeks of treatment discontinued treatment prematurely because of nausea. For patients with intolerable nausea, dose reduction should be considered. *Effect of smoking cessation*. Physiological changes resulting from smoking cessation, with or without treatment with CHANTIX, may after the pharmacokinetics or pharmacodynamics of some drugs, for which dosage adjustment may be necessary (examples include theophylline, warfarin and insulin). Drug Interactions Based on varenicline characteristics and clinical experience to date, CHANTIX has no clinically meaningful pharmacokinetic drug interactions (See Full Prescribing Information, CLINICAL PHARINACOLOGY, Drug-Drug Interactions). Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis. Lifetime carcinogenicity studies were parformed in CD-1 mice and Spraque-Davley rats. Three was no evidence of a carcinogenic effect in mice administred varenicline by oral gavage for 2 years at doses up to 20 mg/kg/day) ty arai gavage for 2 years. In male rats (n = 65 per sex per dose group), incidences of hiberomat (unro, 5 mg/kg/day, 23 times the maximum recommended human daily exposure based on AUC). The clinical relevance of this finding to humans has no theen establicat. There was no evidence of acricongeneics there athere at this. Mutagenesis,

Mutagenesis. Varenicline was not genotoxic, with or without metabolic activation, in the following assays: Ames bacterial mutation assay; mammalian CH0/HGPRT assay; and tests for cytogenetic aberrations in vivo in rat bone marrow and in vitro in human lymphocytes. Impaintent of pertuitive. There was no evidence of impaintent of fertility in either mate ofer mate Sprague-Dawley rats administered varenicine succinate up to 15 mg/kg/day (67 and 36 times, respectively, the maximum recommended human daily exposure based on AUC at 1 mg BID). However, a decrease in fertility was noted in the offspring of pregnant rats who were administered an oral dose of 15 mg/kg/day (36 times the maximum recommended human daily exposure based on AUC at 1 mg BID). This decrease in fertility in the offspring of treated female rats was not evident at an oral dose of 3 mg/kg/day (9 times the maximum recommended human daily exposure based on AUC at 1 mg BID).

fertility in the offspring of treated female rats was not evident at an oral dose of 3 mg/kg/day (9 times the maximum recommended human daily exposure based on AUC at 1 mg BD). **Pregnancy** Crepronancy Category C. Varenicline succinate was not teratogenic in rats and rabbits at oral doses up to 15 and 30 mg/kg/day, respectively (36 and 50-times the maximum recommended human daily exposure based on AUC at 1 mg BID, respectively). **Nonteratogenic effects** Varenicline succinate has been shown to have an adverse effect on the fetus in animal reproduction studies. Administration of varenicline succinate to pregnant rabbits resulted in reduced fetal weights at an oral dose of 30 mg/kg/day (50 times the human AUC at 1 mg BID). There are no adverse effect on the fetus in animal reproduction studies. Administration of varenicline succinate to pregnant rabbits resulted in reduced fetal weights at an oral dose of 30 mg/kg/day (50 times the maximum recommended duily huma reposure based on AUC. In addition, in the offspring of pregnant rats treated with varenciline succinate there were decreases in fertility and increases in auditory startle response at an oral dose of 15 mg/kg/day (36 times the maximum recommended human daily exposure based on AUC at 1 mg BID). There are no adequate and weil-controled studies in pregnant woren. CHANTTX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. **Nursing mothers** Although it is not known whether this drug is excreted in human milk, antimal studies have demonstrated that varenicline can be transferred to nursing pups. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from CHANTTX, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Labor and delivery. The potential effects of CHANTTX is not recommended for use in patients bundler 18 years of gae. **Centr** 

ation for Patients:

Patients should be instructed to set a date to quit smoking and to initiate CHANTIX treatment one week before the quit date.
Patients should be instructed to set a date to quit smoking and to initiate CHANTIX treatment one week before the quit date.
Patients should be advised that CHANTIX should be taken after eating, and with a full glass of water.
Patients should be instructed how to fittate CHANTIX, toginning at a dose of 0.5 mg/day. Prescribers should explain that one 0.5 mg tablet should be taken in the morning and one 0.5 mg tablet should be taken in the evening.
Patients should be advised that, after the first seven days, the dose should be increased to one 1 mg tablet in the morning and one 1 mg tablet in the evening.

1 mg tablet in the evening.
• Patients should be informed that nuese and insomina are side effects of CHANTX and are usually transient; however, patients should be informed that nuesea and insomina are side effects of CHANTX and are usually transient; however, patients should be advised that if they are persistently troubled by these symptoms, they should notify the prescribing physician so that a dose retruitive error be completed.

We define the considered. Patients should also be provided with educational materials and necessary counseling to support an attempt at quitting smoking. Patients should le informed that some medications may require dose adjustment after quitting smoking. Patients intending to become pregnant or planning to breast-feed an infant should be advised of the risks of smoking and risks and benefits of smoking cessation with CHANTDK.

benefits of smoking cessation with CHANTIX. **ADVERSE REACTIONS** During the premarketing development of CHANTIX, over 4500 individuals were exposed to CHANTIX, with over 450 treated for at least. 24 weeks and approximately 100 for a year. Most study participants were treated for 12 weeks or less. In Phase 2 and 3 placebo-controlled studies, the treatment discontinuation rate due to adverse events in patients dosed with 1 mg BID was 12% for CHANTIX compared to 10% for placebo in studies of three months' treatment. In this group, the discontinuation rates for the most common adverse events in CHANTIX treated patients were as follows: nausea (3% vs. 0.5% for placebo), headache (0.6% vs. 0.9% for placebo), insomnia (1.2% vs. 1.1% for placebo), and abnormal dreams (0.3% vs. 0.2% for placebo). Adverse Events were categorized using the Medical Dictionary for Regulatory Activities (MedDRA, Version 7.1).

The most common adverse events associated with CHANTIX (>5% and twice the rate seen in placebo-treated patients) were nausea, sleep disturbance, constipation, flatulence, and vomiting. Smoking cessation, with or without treatment, is associated with nicotine

withdrawal symptoms. The most common adverse event associated with CHANTIX treatment is nausea. For patients treated to the maximum recommended dose of 1 mg BID following initial dosage tilration, the incidence of nausea was 30% compared with 10% in patients taking a comparable placebo. Nausea was generally described as mild or moderate and often transient; however, for some subjects, it was persistent throughout the treatment period. Table 3 shows the adverse events for CHANTIX and placebo in the 12 week fixed dose studies with titration in the first week (Studies 2 (titrated arm only), 4, and 5). MedDRA High Level Group Terms (HLG1) reported in 2 5% of patients in the CHANTIX 1 mg BID dose group, and more commonly than in the placebo group, are listed, along with subordinate Preferred Terms such as 1.5% more frequent than placebo). Closely related Preferred Terms such as 1.5% more frequent than placebo. Jourdeol to relate Preferred Terms such as 1.5% more frequent than placebo. Leatebo, but on the treatment period. CHANTIX patients (and at least 0.5% more frequent than placebo). Closely related Preferred Terms such as "insomnia", 'Middle insomnia', 'Early morning awakening' were grouped, but individual patients reporting two or more grouped events are only counted once.

Table 3: Common Treatment Emergent AEs (%) in the Fixed-Dose, Placebo-Controlled Studies ( $\geq$ 1% in the 1 mg BID CHANTIX Group, and 1 mg BID CHANTIX at least 0.5% more than Placebol

SYSTEM ORGAN CLASS	CHANTIX	CHANTIX 1mg	Placebo
High Level Group Term Preferred Term	0.5 mg BID N=129	1mg BID N=821	N=805
GASTROINTESTINAL			
GI Signs and Symptoms			
Nausea	16	30	10
Abdominal Pain*	5	7	5
Flatulence	9	6	3
Dyspepsia	5	6 5 5	3
Vomiting	1	5	2
GI Motility/Defecation Conditions			
Constipation	5	8	3
Gastroesophageal reflux disease	1	1	0
Salivary Gland Conditions			
Dry mouth	4	6	4

© 2006 Pfizer Inc

Dr. Alpesh Amin said at the annual meeting of the ACCP.

He reported on 196,104 medical patients at 227 U.S. hospitals participating in the Premier's Perspective national inpatient administrative database. The study period was January 2002 through September 2005.

All of the nearly 200,000 patients were at least 40 years old, hospitalized for a minimum of 6 days, possessed at least one risk factor for VTE, and were without contraindications to anticoagulation.

The most common admitting diagnosis was severe lung disease, followed by heart failure, cancer, and acute myocardial infarction.

The appropriateness of thromboprophylaxis was determined by comparing daily use of mechanical compression devices and/or anticoagulants with what was recommended for patients in a given risk category in the ACCP guidelines. To be deemed appropriate, preventive therapy had to be in accord with the recommendations in terms of prophylaxis type

(Table 3 continued) PSYCHIATRIC DISORDERS Sleep Disorders/Disturbances 19 9 13 5 18 13 Abnormal dreams Sleep disorder Nightmare NERVOUS SYSTEM Headache Headache Neurological Disorders NEC Dysgeusia Somnolence 19 15 13 Lethargy GENERAL DISORDERS General Disorders NEC Fatigue/Malaise/Asthenia RESPIR/THORACIC/MEDIAS Respiratory Disorders NEC Rhinorrhea Duespece 6 0 2 0 1 Dyspnoea Upper Respiratory Tract Disorder SKIN/SUBCUTANEOUS TISSUE Epidermal and Dermal Conditions Rash 2 3 Pruritis METABOLISM & NUTRITION Appetite/General Nutrit. Disorders Increased appetite Decreased appetite/Anorexia 4 3 2

\* Includes PTs Abdominal (pain, pain upper, pain lower, discomfort, tenderness, distension) and Stomach discomfort \*\* Includes PTs Insomnia/Initial insomnia/Middle insomnia/Early morning awakening

The overall pattern, and the frequency of adverse events during the longer-term trials was very similar to that described in Table 3, though several of the most common events were reported by a greater proportion of patients. Nausea, for instance, was reported in 40% of patients treated with CHANTIX 1 mg BID in a one-year study, compared to 8% of placebo-treated patients.

Though several of the most common events were reported by a greater proportion of patients. Nausea, for instance, was reported in 40% of patients treated with CHANTX 1 mg BD in a one-year study, compared to 8% of placeb-treated patients.
 Following is a list of treatment-emergent adverse events reported by patients treated with CHANTX during all clinical trials. The listing does not include those events laredy listed in the previous tables or elsewhere in labeling, those events for which ad ung cause was remoted in 40% of patients.
 Following is a list of treatment-emergent adverse events tables or elsewhere in labeling, those events for which ad ung cause was remote, those events which were so general as to be uninformative, and those events for which ad ung cause was remoted, those events for which ad ung cause was remoted, those events for which ad ung cause was ended, thereatening. BLOOD AND LYMPATIC SYSTEM DISORDERS. Infrequent: Anenia, Lymphadenopathy. Rare. Leukocytosis, Thrombocytopenia, Splenomegaly. CARDIAC DISORDERS. Infrequent: Tunitus, Vertigo.
 Rare. Deatiness, Menier's disease. ENDOCRINE DISORDERS. Infrequent: Tunitus, Vertigo.
 Rare Deatines, Menier's disease. ENDOCRINE DISORDERS. Infrequent: Tunitus, Vertigo.
 Rare Deatines, Menier's disorder, Photophola, Vitreous floaters. GASTROINTESTINAL DISORDERS. Infrequent: Carlaia chuters, Carlaia chuters, Curvent ascular disorder, Photophola, Vitreous floaters. GASTROINTESTINAL DISORDERS. Infrequent: Carlaia chuteration. Carlaia chuters SVSTEM DISORDERS. Infrequent: Liper studies and the system and

DRUG ABUSE AND DEPENDENCE Controlled Substance Class Varenicline is not a controlled substance. <u>Humans</u>: Fewer than 1 out of 1000 patients reported euphoria in clinical trials with CHAITX. At higher doses (greater than 2 mg), CHAITIX produced more frequent reports of gastrointestinal disturbances such as nausea and vomiting. There is no evidence of dose-escatation to maintain therapeutic effects in clinical studies, which suggests that tolerance does not develop. Abrupt discontinuation of CHAITIX was associated with an increase in intrability and siege disturbances in up to 3% of patients. This suggests that, in some patients, varenicine may produce mild physical dependence which is not associated with addiction. In a human laboratory abuse liability study, a single oral dose of 1 mg varenicline dind produced my significant positive on regative subjective responses in molexes. In non-smokers, Imguiss. Studies in rodents have shown that varenicline produced full generalization to the incoline cue. In self-administration studies, the deprete which is incolers behavioral responses sims to those produced by nicotine. In rats trianed to discriminate incolme from saline, varenicine produced full generalization to the incoline cue. In self-administration studies, the deprete which varenicline trointer is defined upon the requirement of the task. Rats trained to test-fadminister incolme under easy conditions continued to self-administer varenicline to a degree comparable to that of nicctine, however in a more demanding task, rats self-administrated varenicline to a lesser extent than nicotine. Varenicline pretreatment also reduced nicotine self-administration. **OVERDOSAGE** 

e of overdose, standard supportive measures should be instituted as required. Varenicline has been shown to be dialyzed in s with end stage renal disease (see Full Prescribing Information, CLINICAL PHARMACOLOGY, Pharmacokinetics, acokinetics in Special Patient Populations), however, there is no experience in dialysis following overdose. DOSAGE AND ADMINISTRATION

Usual Dosage for Adults Smoking cessation therapies are more likely to succeed for patients who are motivated to stop smoking and who are provided additional advice and support. Patients should be provided with appropriate educational materials and counseling to support the quit attempt. The patient should set a date to stop smoking. CHANTX dosing should start one week before this date. CHANTX should be taken after eating and with a full glass of water. The recommended dose of CHANTX is 1 mg twice daily following a 1-week titration as follows:

Days 1-3:	0.5 mg once daily
Days 4–7:	0.5 mg twice daily
Days 8–End of treatment:	1 mg twice daily

Patients who cannot tolerate adverse effects of CHANTIX may have the dose lowered temporarily or permanently. Patients should be treated with CHANTIX for 12 weeks. For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks treatment with CHANTIX is recommended to further increase the likelihood of long-term abstimence. Patients who do not succeed in stopping smoking uring 12 weeks of initial therapy, or whor relapse after treatment, should be encouraged to make another attempt once factors contributing to the failed attempt have been identified and addressed. Snecial Ponulations

Special Populations Patients with impaired renal function. No dosage adjustment is necessary for patients with mild to moderate renal impairment. For patients with severe renal impairment, the recommended starting dose of CHANTIX is 0.5 mg once daily. Patients may then titrate as needed to a maximum dose of 0.5 mg twice a day. For patients with End-stage renal disease undergoing hemodialysis, a maximum dose of 0.5 mg once daily may be administered if tolerated well (see Full Preschling Information, CLINICAL PHARMACOLOGY, Pharmacokinetics, Pharmacokinetics in Special Populations, Renal impairment). Dosing in elderly patients and patients with impaired hepatic function. No dosage adjustment is necessary for patients with hepatic impairment. Because elderly patients are more likely howe docreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see PRECAUTIONS, Geriatric Use). Use in children Safety and effectiveness of CHANTIX in pediatric patients have not been established; therefore, CHANTIX is not recommended for use in patients under 18 years of age.

and duration as well as daily dosage.

Nearly 62% of patients received some form of VTE prophylaxis. However, only 33.9% received appropriate prophylaxis in keeping with ACCP guidelines, which since the mid-1980s have been the acknowledged gold standard, according to Dr. Amin, professor and vice chair of medicine and head of the hospitalist program at the University of California, Irvine.

The highest rate of appropriate VTE prophylaxis—49%—occurred in the nearly 9,000 patients hospitalized for ischemic stroke. Among MI patients, 43% received appropriate prophylaxis, as did 40% with heart failure, 31% with lung disease, and 27% with cancer.

VTE has become an increasingly highvisibility issue in recent years. It has been estimated to cause 300,000 deaths per



adherence to VTE

prophylaxis 'is a

significant concern for us across

the nation.'

DR. AMIN

year—about the same as acute MI, and more than breast cancer, HIV, liver disease, and accidents combined. An effort is underway to incorporate VTE prophylaxis rates into core hospital quality performance measures starting in 2008. March is now national Deep Venous Thrombosis Awareness Month. Airlines make an effort

to educate passengers about the problem on long international flights.

To see if this increased public attention to VTE has been accompanied by a temporal trend for improved rates of appropriate prophylaxis, the investigators analyzed nearly 3 years of quarterly data. They found the rate increased over time, but only modestly, from nearly 30% in early 2002 to 40% in late 2005.

The low rate of adherence to VTE prophylaxis "is a significant concern for us across the nation," Dr. Amin said.

They also analyzed the data by geography, payment type, bed size, rural versus urban hospitals, teaching versus nonteaching hospitals, and whether patients were admitted through the emergency department or by a referring physician.

Only about one-third got appropriate prophylaxis no matter how you broke it down. We couldn't find one area where we were doing a wonderful job in terms of prophylaxis. There's more to do," he said.

The investigators are currently preparing individual performance reports for each of the 227 participating hospitals to use in their quality improvement programs. They are also reanalyzing the data to see how prophylaxis rates correlate with outcomes.

In addition, they are updating their results by incorporating adherence rates to the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy guidelines. In the initial study, the investigators used the sixth version of the guidelines, which was the newest version for most of the study period.

Rx only

All rights reserved

#### OVERDOSAGE

#### **CRITICAL CARE MEDICINE** 7

### Statins, Angiotensin-II Receptor Blockers Curbed Sepsis Deaths

**BY BRUCE JANCIN** Elsevier Global Medical News

SALT LAKE CITY — Being on a statin

and/or angiotensin-II receptor blocker at the time of hospitalization for sepsis is associated with significantly reduced 30-day mortality, Dr. Eric Mortensen said at the annual meeting of the American College of Chest Physicians.

This observation from a large retrospective cohort study raises an intriguing hypothesis: Perhaps starting septic patients on one or both medications at the time of admission could reduce mortality, added Dr. Mortensen of the South Texas Veterans Healthcare System, San Antonio.

He reported on 3,018 patients in the national Veterans Affairs ad-

ministrative database hospitalized for sepsis during 2000. In all, 99% were male, with a mean age of 74 years. Their 30-day all-cause mortality was 27%.

At admission, 16% of patients were on a statin, 35% were on an angiotensin-converting



Statin users had a 55% reduction in relative risk of 30-day mortality; ARB patients had a 61% reduction. DR. MORTENSEN

enzyme (ACE) inhibitor, and 4% were on an angiotensin-II receptor blocker (ARB). After adjustment for potential confounders, including comorbidities, demographic variables,

and use of other medications, statin users had a 55% reduction in relative risk of 30-day mortality. Patients on an ARB had a 61% risk reduction, compared with those not on an ARB. However, outpatient ACE inhibitor therapy had no effect on mortality.

Dr. Mortensen noted that both statins and ARBs have immunomodulatory properties that make a survival benefit in septic patients plausible. Simvastatin and losartan were the most frequently prescribed agents in this VA cohort.

Audience members cautioned that the results could be explained by the healthy user effect—the

notion that statin and ARB users may have other health-promoting behaviors enabling them to better survive sepsis. Dr. Mortensen agreed, adding that only a prospective randomized trial can rule that out. He and his coworkers are planning a pilot study.

### Septic Shock May Trigger Brain Atrophy in Survivors

BARCELONA — Septic shock with prolonged mechanical ventilation may take a toll on the brain, both functionally and physiologically.

Three years after patients survived an episode of severe septic shock, their brains showed more central atrophy than did the brains of matched, healthy controls. Survivors also were more likely to have cognitive impairment than were controls, Dr. Robertus Bisschops said at the annual congress of the European Society of Intensive Care Medicine.

Dr. Bisschops of the University Medical Center Utrecht, the Netherlands, examined the effect of severe sepsis on cognition and brain structure in 14 patients who had survived the illness and 42 healthy agematched controls. The sepsis survivors (mean age 58 years at the time of MRI) had been mechanically ventilated during their illness for a mean of 3 weeks.


All subjects took a battery of 10 neuropsychological tests, including a depression scale and an intelligence quotient test; cognitive dysfunction was defined as abnormal results on three or more tests.

Three of the survivors were depressed; most of the surviviors (94%) had abnormal results on one neuropsychological test; 65% had abnormal results on two tests; and 29% had abnormal results on three tests, meeting the criteria for cognitive dysfunction.

White matter lesions occurred in 65% of the patients—not significantly different from among controls. However, survivors did have a significantly increased bicaudate ratio than did controls (0.54 vs. 0.43), indicating central brain atrophy. The bicaudate ratio in cognitively impaired patients tended to be higher, though not significantly higher, than it was in survivors with normal cognitive function.

Survivors also had slightly, but not significantly, higher sulcal grades than did controls (mean 3 vs. 2). Higher sulcal grades are associated with decreased cognitive functioning, Dr. Bisschops said.

-Michele G. Sullivan



### You get it. Right out of the box.

Virus. What virus? No learning curve. No-brainer. Save on a Mac and Apple software with your ACCP education discount.

www.apple.com/edu/accp

### **Spirometry Vastly Underutilized in COPD Management**

BY PATRICE WENDLING Elsevier Global Medical News

TUCSON, ARIZ. — Few patients with chronic obstructive pulmonary disease receive spirometry, recommended medication combinations, and stage-appropriate therapy, results of a retrospective analysis of 200 outpatients demonstrated.

Instead, investigators noted the prema- i

ture use of inhaled steroids and an early indication for oxygen use prior to maximizing other stage treatments, Dr. Pompeyo Chavez and Dr. Navkiran Shokar reported in a poster at the annual meeting of the North American Primary Care Research Group.

A third of patients were diagnosed on clinical grounds, even though the 1998 Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations established spirometry as the diagnostic standard.

The investigators reviewed the records of 200 randomly selected patients attending a university-affiliated family medicine clinic for chronic obstructive pulmonary disease (COPD) over a 1-year period. Each hospital chart was reviewed for spirometry results going back 10 years.

The patients' mean age was 65 years (range 41-91 years); 104 patients were female, 144 were Caucasian, 45 were African American, and 11 were Hispanic. A total of 128 patients had public insurance, 41 had private insurance, 10 had mixed insurance,



Obstacles to stage-appropriate therapy include money and low spirometry utilization. DR. CHAVEZ

17 were indigent-care patients, and 4 patients had no insurance. The prevalence of smoking (45%) in

these patients was significantly higher than in the general population (20%-25%), reported the authors, both with the family medicine department at the University of Texas, Galveston. Physicians did well in counseling and offering alternative regimens (68%).

Only 117 patients (59%) had spirometry performed in the previous 10 years. Spirometry confirmed a COPD diagnosis in 102 patients (87%), and did not confirm in 15 patients (13%).

Within 3 months of spirometry, the results were mentioned in 71 cases (61%), severity was noted in 43 cases (37%), and medication was changed in only 48 cases (41%).

Low spirometry use may have occurred because patients had to be referred to a pulmonary laboratory in the institution for testing, and because results may not be fol-

lowed correctly when patients don't always return to the same physician at the clinic, Dr. Chavez said in an interview. In 102 patients whose COPD stage was known from spirometry, 9 were stage 1, 36 were stage 2, 48 were stage 3, and 9 were stage 4.

Stage-appropriate therapy, based on GOLD criteria, was used in 3 stage 1 patients (33%), in 2 stage 2 patients (5.5%), in 13 stage 3 patients (27%), and in 3 stage 4 patients (33%).



Although spirometry is considered the diagnostic standard, only 59% of patients received such testing in the past decade.

Overall, 45% of patients received medication combinations not recommended by GOLD criteria, and 22% received medications that were not stage-appropriate combinations according to the criteria, he said.

Short-acting bronchodilators, which are appropriate for all stages of COPD, were used by most (93.5%) patients. Inhaled steroids and oxygen, which are reserved for severe or very severe COPD patients, were used by 42% and 17% of such patients, respectively.

Obstacles to stage-appropriate therapy include money, low spirometry utilization, and lack of awareness of GOLD criteria, Dr. Chavez said. "If spirometry were readily available in the office, I think we'd be more prone to use it," he said. "In Europe they do. There's no research on this in the United States, but my guess is they always refer, which might be a barrier."

#### Dr. Jeffrey Hawkins, FCCP, comments:

This is an interesting look at general medical patients in a family medicine clinic. It may well represent the broader population of all nonspecialty medical care and validate the continued need for ongoing education of our medical colleagues. We should be advocates for the use of basic spirometry and the clinical usefulness of using the therapeutic recommendations of the GOLD guidelines.

### **Studies Test Valves, Biologics**

#### **Bronchoscopic** • from page 1

said that although LVR surgery didn't increase survival in the 180-patient National Emphysema Treatment Trial as a whole, it did improve survival, pulmonary functional capacity, and health status in the subset of participants with heterogeneous, predominantly upper lobe emphysema and poor exercise capacity (N. Engl. J. Med. 2003;348:2059-73).

The price of surgical LVR was steep: a 30day mortality of about 5%, close to 50% major morbidity, and lengthy hospitalization. This has prompted intense research interest in developing procedures to reduce the volume of hyperinflated diseased lung without actually cutting out tissue, added Dr. Sterman, an interventional pulmonologist at the University of Pennsylvania, Philadelphia. He disclosed that he has been a consultant and a member of the scientific advisory committee for Spiration Inc.

He was lead investigator in a multicenter U.S. pilot study of Spiration Inc.'s Intrabronchial Valve (IBV), a one-way valve allowing air to escape from diseased portions of the lung, enabling the lungs to work more efficiently. Five hundred twenty IBV valves were implanted in the upper lobes of 75 emphysema patients in the nonrandomized study, which typically involved an overnight hospital stay.

Forty-six patients benefited, showing sig-

nificantly improved general and diseasespecific health status and reduced oxygen consumption with up to 1 year of followup. Complications in this subgroup were limited to one case of bronchospasm and one flare of COPD.

Follow-up CT scans at 3 and 6 months showed significant

reduction in the volume of the upper lobes of the responders, compared with their lower lobes, which increased in both volume and vascularity. This suggests the clinical benefits resulted at least in part from a redirection of ventilation and perfusion to the relatively spared lower lung segment, he explained.

Responders were

younger than 75 years old, had fewer lung segments treated, and didn't have any valves placed in the lingula. The findings will be incorporated into the upcoming large randomized trial.

Dr. Celli reported on 15 patients who have undergone a total of 21 biologic LVR

treatment sessions involving instillation of a biodegradable agent. "It has one advantage compared to the other good ideas out there: There's no foreign body left inside the individual," the physician noted.

The procedure, being developed by Aeris Therapeutics Inc., is definitely safe, said Dr. Celli, who has received research funding from the company. The only associated adverse events have been the minor sort common with flexible bronchoscopy. All



Biologic LVR has one advantage over other good ideas: 'There's no foreign body left inside.' DR. CELLI en the minor sort come bronchoscopy. All patients were by protocol discharged the day after the procedure, but most could have gone home the same day, he said. As for efficacy, early results look promising; but it will take many

promising; but it will take many more patients and longer follow-up to know for sure, Dr. Celli added.

The treatment concept involves identifying diseased

areas of lung, then instilling the biologic agent to induce atelectasis and shrink the volume so that much healthier but compressed lung tissue is allowed to expand.

A dose-response effect was apparent. The patients who have shown clinically meaningful improvements in vital capacity and exercise capacity were the ones who received the most extensive treatment: bilateral therapy targeting up to 10% of total lung volume. Future clinical trials may target 20%-30%.

The biologic procedure's safety lends itself to repeat sessions as additional areas of lung deteriorate. One appealing but as yet untested strategy: perform biologic LVR, measure lung function, then decide if the patient needs to come back in a few weeks for further LVR to optimize results.

The patient with the best response to treatment to date is swimming for exercise and still going strong 14 months after treatment. To physicians familiar with severe COPD, that's nothing short of miraculous, he said. But investigators haven't figured out why he's doing so well while some others who underwent extensive treatment didn't have major responses.

Nonetheless, the future of nonsurgical interventions looks bright for patients with severe COPD, who traditionally have had few options other than the faint prospect of lung transplantation. Dr. Celli offered a final bit of advice to his fellow chest physicians: "Go learn bronchoscopy."

**Dr. Robert Cerfolio, FCCP, comments:** The future of nonsurgical methods to provide lung volume type procedures for patients with heterogenous emphysema is bright. Celli and colleagues have presented another way besides one-way valves. The data may be immature, but the promise of this technology is high.



The IBV allows air Biolo to escape from one diseased portions over of the lung, ideas enabling it to work fore more efficiently.

ed. DR. STERMAN

**IN A YEARLONG STUDY OF** 

**108 PATIENTS, THERMOPLASTY** 

LED TO A SIGNIFICANT DROP IN

**ASTHMA EXACERBATIONS,** 

**COMPARED WITH DRUG THERAPY.** 

### **Bronchial Thermoplasty May Cut Asthma Exacerbations**

The investigational outpatient procedure shows promise for long-term improvement in quality of life.

**BY BRUCE JANCIN** Elsevier Global Medical News

SALT LAKE CITY — Bronchial thermoplasty is an innovative outpatient procedure showing potential as a long-term nondrug treatment for asthma, Dr. Michel Laviolette said at the annual meeting of the American College of Chest Physicians.

The investigational procedure, performed through a standard flexible bronchoscope, resulted in a significant decrease in asthma exacerbations and improved asthma-related quality of life, compared with medical management, in the yearlong, randomized, 108-patient, multicenter Asthma Intervention Research (AIR) trial, reported Dr. Laviolette of Laval University, Quebec City. Asthmatx Inc., which is developing bronchial thermoplasty using its Alair catheter system, funded the study.

Bronchial thermoplasty involves the use of catheter-delivered radiofrequency energy to thermally ablate airway smooth muscle. Over the course of three halfhour sessions, interventional pulmonologists treat all reachable 3- to 10-mmdiameter airways distal to the main stem bronchi, sparing only the right middle lobe.

In dog studies, there is almost no residual smooth muscle mass after bronchial thermoplasty.

Based upon the encouraging results of the AIR trial, AIR2 is now under way. It is a 300-patient international randomized trial featuring a sham procedure in controls.

Dr. Laviolette explained that AIR trial participants were randomized to standard management with inhaled corticosteroids and long-acting  $\beta$ -agonists, or standard management plus bronchial thermoplasty.

All subjects had moderate to severe persistent asthma.

During 1 year of follow-up, the bronchial thermoplasty group experienced a 40% increase in the number of symptom-free days over baseline, which was significantly better than the 13.7% increase in controls. The mean number of puffs of rescue medication required per week dropped by 90% in the thermoplasty group, compared with 10% in controls. Exacerbation rates during a 2-week destabilization period without long-acting  $\beta$ -agonists were 50% lower, compared with baseline in the

bronchial thermoplasty group, but not significantly different than at baseline in the control group.

In addition, thermoplasty recipients scored significantly better than controls

on the Asthma Quality of Life Questionnaire and Asthma Control Questionnaire.

There was no significant difference between the two groups in forced expiratory volume in one second  $(FEV_1)$  at 1 year.

In terms of safety, bronchial thermoplasty was associated with a transient worsening of asthma symptoms and airway irritation that typically started the day after treatment and resolved within a week. There were 407 such adverse respiratory events—including dyspnea, cough, wheezing, and night awakening—in the thermoplasty group, compared with 106 such events in the control group. Sixty-nine percent of the events were classified as mild and only 3% as severe in nature.

There were no lingering or unexpected adverse events; be-

tween 1 week and 1 year post treatment, there were three respiratoryrelated hospitalizations in each study group.

Long-term safety and efficacy data are needed, and the

treatment is considered experimental. When asked how long the benefits last,

Dr. Laviolette replied that in dog studies, a favorable response to the methacholine challenge test persists at 3 years and counting.

Follow-up in asthma patients isn't as long yet, but improvement is retained at the 2-year mark.

Dr. Laviolette declared that he has no financial relationship with Asthmatx.

### **New Drugs Are on the Horizon**

#### Pipeline • from page 1

plus an inhaled corticosteroid is in the wings as well, predicted Dr. Lazarus, professor of medicine and director of the chest faculty practice at the University of California, San Francisco.

Here's what else is on the horizon for the treatment of COPD:

► New  $\beta_2$ -agonists. The new ones have in common the convenience and improved adherence achieved through once-daily dosing. Arformoterol is the (R,R)-isomer of formoterol. It avoids the potentially proinflammatory effects of the parent drug's S-isomer. It is already marketed as a nebulized solution.

Indacaterol is a once-daily long-acting  $\beta$ -agonist that brought substantial improvement in forced expiratory volume in 1 second (FEV<sub>1</sub>) in a recently presented but as yet unpublished randomized trial involving 635 patients with moderate to severe COPD.

Several other once-daily agents are early enough in development that they haven't been assigned names. Also in the pipeline is tulobuterol patch therapy, a novel way to achieve long-acting bronchodilation, Dr. Lazarus said at the satellite symposium.

► Anticholinergics. Here again, the emphasis is on developing once-daily drugs with long duration of action.

Glycopyrrolate is not a new drug, but it is being developed as a nebulized solution for asthma and COPD. It blocks methacholine-induced bronchoconstriction for about 30 hours. In addition, a couple of new anticholinergics are in the pipeline.

▶ **Phosphodiesterase** E4 inhibitors. They target the inflammation that is a hallmark of COPD. They reduce the activity of neutrophils, macrophages, and CD8+ T-lymphocytes while also decreasing expression of tumor necrosis factor– $\alpha$  and other inflammatory mediators. Clinically, they may reduce COPD exacerbations and improve FEV<sub>1</sub>, more so in patients with severe than moderate COPD.

GlaxoSmithKline Inc. has received an "approvable" letter from the Food and Drug Administration for its twice-daily cilomilast (Ariflo). Altana AG's once-daily roflumilast is well into phase III clinical trials. Tetomilast is far earlier along.

Because the anti-inflammatory profile of the PDE4 inhibitors differs from that of corticosteroids, there is research interest in using the two together. Ongoing trials are assessing the role of the PDE4 inhibitors as stand-alone vs. combination therapy, Dr. Nicola A. Hanania, FCCP, said at a satellite symposium sponsored by Altana.

Dr. Lazarus, however, isn't convinced the new PDE4 inhibitors are going to have a major impact.

"They're certainly more specific than the old PDE inhibitors like theophylline, but the bugaboo still seems to be side effects, primarily gastrointestinal," he said. "The data on these agents suggest their efficacy has to be counterbalanced by the high prevalence of GI upset and diarrhea. I'm not terribly optimistic about these in the future."

Dr. Hanania disagreed, pointing out that patients didn't discontinue PDE4 therapy because of GI side effects in the large phase III trials. The GI side effects usually are manageable and are confined largely to the first 3 weeks, added Dr. Hanania of Baylor College of Medicine, Houston.

► Antioxidants. Oxidative stress is clearly key in COPD. Enthusiasm ran high regarding the therapeutic potential of oral N-acetylcysteine to turn off the oxidative process and interrupt the inflammatory cascade—at least until the large Bronchitis Randomized on NAC Cost-Utility Study (BRONCUS) reported negative results (Lancet 2005;365:1552-60). Critics of the study argue the dose was far too low. Also in the antioxidant pipeline for COPD, albeit in the preclinical stage, are superoxide dismutase analogs.

► Anticytokine therapy. TNF- $\alpha$  plays a key role in perpetuating the neutrophilic inflammatory response in COPD, so it seems logical that an agent such as infliximab or etanercept would be useful. But Dr. Hanania was a coinvestigator in a recently completed 300-patient trial in which anticytokine therapy showed a disappointing lack of benefit.

An antibody to another inflammatory cytokine important in COPD—interleukin-8—is now in clinical trials. "I think there's some potential for this," Dr. Lazarus said.

▶ Inhaled vasoactive intestinal peptide. VIP is known to have anti-inflammatory, bronchodilator, and vasodilator properties. At the ACCP meeting, Dr. Bernhard Burian presented preliminary data from the first 25 patients to complete the ongoing 6-month double-blind placebo-controlled VIP-COPD trial. Participants inhaled 200 mcg of aerosolized VIP or placebo four times daily for 3 months, followed by another 3 months of VIP for all.

The study code isn't broken yet, so the most interesting results—VIP vs. placebo—are still to come. But the group as a whole showed significantly improved exercise capacity and quality of life scores along with stable blood gas exchange and essentially no side effects, said Dr. Burian of the Medical University of Vienna.

The short half-life of VIP in the airways because of protease degradation has been

"a huge problem," he added, but the Vienna group has identified several protease-resistant long-acting VIP analogs for use in future clinical trials.

► Histone deacetylase activators. These drugs are being developed in an effort to partially reverse the corticosteroid resistance that plays such an important role in COPD.

Histone deacetylase figures centrally in the mechanism by which steroids turn off inflammation, and in smokers, the enzyme is downregulated. Interestingly, the PDE inhibitor theophylline upregulates histone deacetylase.

▶ **Protease inhibitors.** Matrix metalloproteinases, cathepsins, and neutrophil elastase are produced by neutrophils and macrophages and are an important part of the COPD inflammatory process. Specific inhibitors of these proteases are relatively early in development.

► Statins, macrolide antibiotics, and epidermal growth factor receptor inhibitors. What these drug classes have in common is that none was developed for use in COPD, but all have demonstrated intriguing preliminary suggestions of efficacy now being followed up in more definitive trials.

For example, a large year-long study is looking at the use of low-dose macrolide antibiotic therapy as a means of reducing COPD exacerbations, not through an antimicrobial effect but via the macrolide's systemic anti-inflammatory effect. Epidermal growth factor receptor inhibitors are being studied as a means of downregulating mucus hypersecretion in COPD.

Dr. Hanania disclosed that he has received grants for clinical research from Altana and GlaxoSmithKline, and has served as a consultant to GlaxoSmithKline.

Dr. Lazarus has no research grants from or any other form of financial relationship with any pharmaceutical company.

Ε

Ε

G

#### 

BY DR. MARK J.

**ROSEN, FCCP** 

ports, CHEST 2006 was a major success. Attendance was among the highest

Ν

Ε

W

S

of any of our annual meetings, and participants consistently praised the range and quality of the presentations, the expertise of the speakers, and the delivery of important and useful new information that relates directly to the practice of pulmonary, critical care, and sleep medicine. The mission of the ACCP is to promote the prevention and treatment of diseases of the chest through leadership, education, research, and communication; I think we can all be proud that this meeting served our mission well.

To the casual observer, and probably to most who attend, our annual meetings are executed almost flawlessly, and ACCP staff and members make it all look easy. We should appreciate the enormous

### PRESIDENT'S REPORT Behind the Scenes at CHEST 2006

M

R

Π

effort that it takes to organize a meeting of this size and scope with consistent success. Orchestrating over 350 sessions, with more than 700 faculty requires months of preparation and coordination by scores of people working in the background. The planning process that collects relevant topics, organizes them into effective educational formats, and recruits the best faculty takes months of hard work by the NetWorks and the Program Planning Committee. The annual meeting is also one of the most important ongoing projects for each person on the College staff, and work on the 2007 meeting starts long before the 2006 meeting is over. Each meeting is the direct result of continuous and intense effort by ACCP executive staff and the education, marketing, finance, membership, health affairs, operations, and publications groups and The CHEST Foundation. Around 65 staff members attended CHEST 2006 to work very long hours to keep things moving, troubleshoot inevitable last-minute problems, and, at the end, make it all look easy.

Н

F

Π

The annual meeting is also a convenient venue where we conduct much of the ongoing business of the College. The Board of Regents, Executive Committee, NetWorks, Governors, Pulmonary/Critical Care training program directors, and major committees all meet and plan for the next year. The ACCP enjoys excellent collaborative relationships with a number of other organizations, and the annual meeting is where we move these agendas forward. At CHEST 2006, ACCP leadership met with representatives of the American Thoracic Society, Canadian Thoracic Society, American Association of Critical-Care Nurses, Society of Critical Care Medicine, European Respiratory Society, Asian Pacific Society of Respirology, Society of Thoracic Surgery, National Association of Medical Directors of Respiratory Care, and professional societies from Greece, Portugal, Brazil,

and France. In these sessions, we assessed what we have accomplished together and planned for future efforts in education, policy, and advocacy.

Over the last few years, I have grown increasingly appreciative of the complexity of the ACCP as an organization that serves its mission and membership and in awe of the talents and accomplishments of our staff. I am also delighted that the Nominations Committee named Dr. James A. L. Mathers, Jr., FCCP, to be the ACCP President, 2008-2009. Jim brings a wealth of experience in leadership in the ACCP, The CHEST Foundation, and NAMDRC, along with special expertise in healthcare legislation, regulations, and practice administration. ACCP Presidents of the past, present, and future work as a team, and Jim will surely make an outstanding and unique contribution to our ongoing work. We all look forward to working with him.

## call for abstracts

October 20 - 25, 2007 Chicago, Illinois

### MONDAY, APRIL 30, 2007

Be part of the CHEST 2007 program by submitting an abstract of your original investigative work for presentation during the meeting.

- Gain international exposure. Your work will be presented to an international audience and published in a CHEST supplement.
- Receive feedback from the clinicians likely to use your data in their practices. Health-care professionals in chest and critical care medicine will review and comment on your work.
- Participate with the ACCP in efforts to fight chest diseases. By presenting your findings, you join the ACCP in its mission to advance the prevention and treatment of chest diseases through research and education.
- Compete for ACCP investigative awards. Monetary awards are granted by The CHEST Foundation to investigators whose work is judged to be outstanding by the reviewers.

Abstract submission to CHEST 2007 is FREE. Domestic and international submissions are encouraged. Abstracts will be graded individually on scientific merit and originality. Abstract submission begins early March. Submit online at www.chestnet.org by clicking on the Abstracts and Case Reports Submission link when available. For questions, call (800) 343-2227 or (847) 498-1400.

#### ACCP "LEARN" Scholarship Researching the Educational Impact of Medical Education

The ACCP Continuing Education Committee has launched a groundbreaking scholarship program to award and promote research efforts in continuing medical education (CME) to better understand how education designs impact physicians and clinical outcomes.

Up to \$15,000 will be awarded to support one 2-year study that:

- Impacts the future development of clinically relevant medical education initiatives within the ACCP.
- Identifies and advances the best delivery of medical education.

#### **Applicants must:**

- Be an ACCP member.
- Submit proposals to study learning outcomes of ACCP educational activities and measure the effect on physician knowledge and health-care delivery.
- Complete an online application for this award by January 10, 2007.

Learn more and apply at www.chestnet.org/education/scholarship.





CANADIAN THORACIC SOCIETY SOCIÉTÉ CANADIENNE DE THORACOLOGIE

NEW!

rom all reports, CHES 2006 was a

#### OLL W S Μ F C Ε G F Π н CHEST

### EDUCATION INSIGHTS **Reflections on CHEST 2006 QI Programs**

BY SANDRA ZELMAN LEWIS, PHD ACCP Research Analyst

**O**ne of the major goals of the ACCP's participation in healthcare quality improvement (QI) is to aid ACCP members with QI efforts in their own practices and institutions. Members who attended CHEST 2006 in Salt Lake City were treated to several opportunities to learn about the national movement and how it will influence their daily practice.

The highlight was the CHEST 2006 Keynote Opening Session, an interactive discussion on "Quality Improvement, Performance Measures, and Pay for Performance: Why You Should Care." Distinguished leaders from the National Quality Forum (NQF), Centers for Medicare and Medicaid Services (CMS), American Medical Association Physician Consortium for Performance Improvement

(AMA-PCPI), and American Board of Internal Medicine (ABIM) participated in an informative panel discussion moderated by the Chair of the Quality Improvement Committee (QIC), Dr. Michael Baumann, FCCP. This address touched on the development and endorsement process for performance measures and emerging trends in pay for performance, value-based competition, and how quality is incorporated into the maintenance of board certification.

These themes and others were discussed in two half-day postgraduate courses on "The Use of Evidence-Based Medicine and Practice for the Clinician" followed by "Providing Excellence in Chest Medicine: How Does the Physician Incorporate Quality Improvement and Performance Measures?" These courses analyzed how performance measures are used by third-party payers, realized QI

initiatives in private practice, and how chest physicians can use performance measures in their own practices.

Other sessions offered at CHEST 2006 included: Evidence-Based Guidelines and Performance Measures: A Survival Guide for Clinicians; Accidents and Errors-When Things Go Wrong, jointly sponsored by AACN, ATS, SCCM, and ACCP; Best Clinical Practice Guidelines: How Do We Get From the Clinical Guidelines to Individual Best Practices; and a town hall meeting with the Centers for Medicare and Medicaid Services.

Provide feedback on this year's sessions at whyyoushouldcare@ chestnet.org. Check www.chestnet.org for the debut of the Quality Improvement Committee's Web pages, accessed from the Education drop-down menu. For questions on QI efforts at the ACCP, contact Sandra Zelman Lewis, PhD, at slewis@chestnet.org.

### This Month in CHEST: **Editor's Picks**

IRWIN, FCCP Editor in Chief, CHEST

► The Inescapable Relevance of Bioethics for the Practicing Clinician. Dr. Joseph A. Carrese, MPH; and Dr. Jeremy Sugarman, MPH

Drawing Impairment Predicts Mortality in Severe COPD. Dr. Raffaele Antonelli-Incalzi, et al

► Is Methamphetamine Use Associated With Idiopathic Pulmonary Arterial Hypertension? Dr. Kelly M. Chin, et al

Risk Factors for Extubation Failure in Patients Following a Successful Spontaneous Breathing Trial. Dr. Fernando Frutos-Vivar, et al ▶ Lung Function and Ischemic Stroke Incidence: The Atherosclerosis Risk in Communities Study. Dr. Atsushi Hozawa, et al

Enhancement of Treatment Completion for Latent Tuberculosis Infection With 4 Months of Rifampin. Dr. Alfred A. Lardizabal, et al www.chestjournal.org

BY DR. RICHARD S. CHEST

#### **AMERICAN COLLEGE OF CHEST PHYSICIANS**

**January 18 - 21** Sleep Medicine 2007 Scottsdale, Arizona

March 16 - 18 **Celebration of Pediatric** Pulmonology 2007 San Antonio, Texas

June 22 - 24 Noninvasive Mechanical Ventilation 2007 Montréal, Québec, Canada June 22 - 25 World Asthma Meeting Istanbul, Turkey

#### August 24 - 27 **Sleep Medicine Board Review Course 2007** Phoenix, Arizona

August 24 - 28 **Critical Care Board Review Course 2007** Phoenix, Arizona

August 28 Lung Pathology 2007 Phoenix, Arizona

August 28

**Mechanical Ventilation 2007** Phoenix, Arizona

August 28

American Board of Internal Medicine (ABIM) Critical **Care SEP Module** Phoenix, Arizona

#### August 28

American Board of Internal Medicine (ABIM) Pulmonary **Disease SEP Module** Phoenix, Arizona

August 29 - September 2 **Pulmonary Board Review Course 2007** Phoenix, Arizona

**October 20 - 25 CHEST 2007** Chicago, Illinois

**ACCP-Sponsored Courses** 

**ACCP-Endorsed Courses** 

## EducationCalendar

Learn more about ACCP-sponsored and ACCP-endorsed educational courses. www.chestnet.org/education/calendar.php (800) 343-2227 or (847) 498-1400



Ε

Ε

0

#### CHEST

### INSIDE ACCP The Operations Division: Delivering Service

Μ

R

0

F

**BY DONALD JONES** Vice President, ACCP Operations

The Operations Division is usually the invisible contributor to many of the initiatives of the American College of Chest Physicians.

The product of the Operations Division is SERVICE. A combination of many services provides an infrastructure for the ACCP to conduct its daily business, as well as provide an infrastructure for the future.

The infrastructure is divided into the physical building and the technology behind the operations of the ACCP.

Requests for assistance with purchasing, mailings, shipping, receiving, computer hardware, software issues, and the work environment are addressed by the Operations staff daily.

One of the Operations responsibilities is the maintenance of the ACCP's Northbrook office building. Last year, the Operations Division managed a \$1.2 million renovation project to provide more office space and a more efficient floor plan for the various departments.

The goal of Operations is to provide a safe and professional environment for the staff to conduct business.

The technical side of the Operations Division is usually involved with many of the other divisions strategic initiatives.

These initiatives usually take advantage of the new technologies

#### ACCP PRODUCT OF THE MONTH SLEEP 2: Study Lessons on CD

se this interactive CD program to study the diagnostic tools used in sleep medicine. This updated second edition features 51 casebased questions to mirror clinical experiences, enhance learning through immediate feedback, and offer references for further study SLEEP 2 complements the first SLEEP CD by covering additional topics and a wider range of diagnostic techniques. Product #6633. Order online at the ACCP Store: www.chestnet. org, or call (800) 343-2227.

enabled by the continued evolution of the Internet. Some examples of these new Web-based applications are e-membership; an online membership application; award applications for The CHEST Foundation; and an entirely new system

E

Ν

W

S

for the Education Division, which provides for the online submission of education topics and the review, grading, and acceptance of these topics; and faculty disclosure submissions.

н

F

All of these new systems provide a

much more integrated approach that results in greater productivity for the staff and ACCP members.

In 1995, the Operations Division secured the URL, chestnet.org, and the Web site has been in a continuous

### New Observations in Idiopathic Pulmonary Fibrosis

#### NEWS FROM THE COLLEGE OF H Y S I C I A N S

redesign and enhancement cycle ever since.

Every division utilizes this Web site by providing updated information to post or requesting assistance with how best to utilize the Web as a marketing channel or to provide a new service. This is a great resource to find current information about events or products available from the College.

The Operations infrastructure of the

ACCP is heavily based on technology. The role of the technology infrastructure

is to meet the day to day business requirements, as well as align the technology with the future strategic direction of the ACCP.

The ACCP has used technology as a catalyst for change in organizational restructuring, process consolidation, and new services to the constituents of the ACCP. A look at the past and comparing it with today will highlight the challenges of this responsibility.


In the early 1990s, the College was a much simpler and smaller organization, with an annual budget of  $\sim$ \$7 million, a staff of  $\sim$ 45, and an annual meeting budget of  $\sim$ \$2.5 to  $\sim$ \$3 million dollars.

Today, the ACCP has an annual operating budget of almost three times that amount, a staff of  $\sim$ 76, an annual

\*2 in a series The Nature of IPF: Rapid Fatal Deterioration

Data show that the clinical course of IPF often involves acute (≤4 weeks) fatal deterioration, even in patients with only mild to moderate disease.<sup>1\*</sup>





\*Data from a retrospective analysis of 168 patients with mild to moderate IPF in the placebo arm of a phase 3 trial. Most (89%) of the deaths that occurred were due to IPF-related causes. Nearly half (47%) of these deaths were preceded by a period of deterioration lasting ≤4 weeks.

The insidious nature of IPF and the risk of rapid fatal deterioration may make early referral to a randomized clinical trial or for lung transplantation a good option in patients diagnosed with the disease.<sup>1-4</sup>

Dedicated to a clearer understanding of IPF, InterMune is working to advance care for patients.



References: 1. Martinez EJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142:963-967. 2. Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M, Yamamoto S. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. Am J Roentgenol. 1997;168:79-83. 3. Ambrosini V, Cancellieri A, Chilosi M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J. 2003;22:821-826. 4. American Thoracic Society/European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med. 2000;161:646-664.

meeting budget of ~\$5 to \$6 million dollars, plus a much more active membership—thanks to the introduction of ACCP Net-Works.

The technology landscape has changed tremendously since the 1990s, as well.

The introduction of the Web has enabled the ACCP to offer many more services and products directly to the members.

This new business model of self-service to the constituents of the College allows for 24/7 service to individuals around the world.

The self-service model is gaining momentum, as evidenced by the continued increase in the self purchase of registration for ACCP educational courses.

About 45 % of all registrants are purchasing these directly through the Web without any assistance from the staff.

With the support of leadership, our CEO, and the American College of Chest Physicians members we serve, we will continue to expand and increase products and services online.

All of the services are provided by a very dedicated and talented team of 12 individuals who are technologically very savvy and possess a great service-oriented attitude.

### Coding Updates Webinar

ear them live—the new coding updates for 2007. Ask questions, and understand how to appropriately document to ensure you are getting paid for all the services you provide. Join the ACCP Webinar "Coding and Documentation: Update 2007" on Monday, Jan. 29, at 11:30 am (CST).

More information is available at www.chestnet.org/ education/online/webinar/ or call Joyce Bruno at (847) 498-8120.

#### COMING IN JANUARY... Chicago Hosts CHEST 2007

ook for a wrap-up of the highlights from CHEST 2006 in next month's issue of *CHEST Physician*—plus an exciting glimpse of CHEST 2007 in Chicago, October 20-25, 2007!

## Pulmonary Perspectives

## **Postthrombotic Syndrome: A Need for Attention**

espite major progress over the past 30 years in the diagnosis, prevention, and treatment of venous thromboembolic disease, relatively little remains known about its most common sequela, the postthrombotic syndrome (PTS), also known as the postphlebitic syndrome. It receives little attention in reviews or textbooks.

This lack of attention contrasts with the significant morbidity associated with PTS. Its costs are high in terms of direct costs of care and indirect costs in days lost from work, disability, and diminished quality of life (Kahn et al. *Ann Intern Med* 2002; 162:1144; Kahn et al. *J Thromb Haemost* 2004; 2:21). In the past several years, prospective randomized studies

and reviews have provided new insights into the clinical picture of PTS and have highlighted the need for more information. The purpose of this *Perspective* is to provide a review of what we know and what we need to know about PTS, with a view toward renewed interest among pulmonologists,

internists, and general practitioners.

#### **Definition and Epidemiology**

PTS is a syndrome that occurs after symptomatic or asymptomatic deep venous thrombosis (DVT). Its manifestations are those of venous insufficiency. Aching pain, heaviness, itching, tingling, and cramps in the affected limb are common. Physical findings may include pretibial edema, hyperpigmentation, eczematous changes, venous ectasia, redness, induration, and ulceration. Although PTS had been thought to be a late sequela of DVT, prospective studies have shown that most cases develop within the first 2 years after an acute episode of DVT (Prandoni et al. Ann Intern Med 1996; 125;1; Prandoni et al. Ann Intern Med 2004; 141;249).

While the reported incidence of PTS

#### **Editorial Comment**

This is Dr. Deborah Shure's final article as Editor of *Pulmonary Perspectives*. She leaves a 15-year legacy of editorial leadership, intelligence, wit, and a gift for making the difficult understandable. Her commitment to science and truth is legendary. She has enhanced the lives of many pulmonologists as teacher, mentor, and friend. And I, for one, am ever grateful.

> Dr. Aymarah M. Robles, FCCP Deputy Editor

has ranged from 20 to 100%, the incidence has probably declined with the advent of improved detection and prophylaxis of DVT. The incidence now appears to range from 20 to 50%, with severe disease in 5 to 10% (Kahn. *J Thromb Thrombolysis* 2006; 21:41). Variations in incidence may be related to differences in population risk factors, diagnostic criteria, and prophylaxis.

### Pathophysiology, Etiology, and Risk Factors

Relatively little is known about the pathophysiology of PTS. DVT is thought to damage venous valves with subsequent venous incompetence and venous hypertension. Popliteal reflux, in particular, has been

THE LACK OF ATTENTION CONTRASTS WITH THE SIGNIFICANT MORBIDITY ASSOCIATED WITH PTS. ITS COSTS ARE HIGH IN TERMS OF DIRECT COSTS OF CARE AND INDIRECT COSTS.

associated with development of PTS with or without residual thrombus (Prandoni et al. *J Thromb Haemost* 2005; 3:401). It is important to note that PTS may occasionally occur in the absence of demonstrable venous abnormalities and that significant venous abnormalities may be present post-DVT

without the development of PTS (Johnson et al. *J Vasc Surg* 1995; 21:307). These findings suggest that other factors may be involved, such as damage to the microcirculation or the lymphatic circulation.

The only clearly demonstrated risk factor for PTS is ipsilateral recurrent DVT, which is associated with a 3-fold to 10-fold increased risk (Kahn. *Curr Opin Pulm Med* 2006; 12:299). Other implicated risk factors include older age, obesity, and subtherapeutic oral anticoagulation during the acute episode of DVT (Prandoni et al. *Semin Thromb Hemost* 2006; 32:744). Curiously, factor V Leiden and prothrombin mutations do not appear to be associated with increased risk, despite the increased risk of thrombotic disease with these mutations.

#### Diagnosis

The diagnosis of PTS is largely a clinical one. There is no gold standard and no definitive objective measurement.

The diagnosis can be made with reasonable certainty if there is a history of DVT and the clinical features of PTS described above are present. Since PTS can occur after asymptomatic DVT (Wille-Jorgensen et al. Thromb Haemost 2005; 93:236), the diagnosis may need objective testing in the absence of a history of DVT. If clinical signs are present without a history of DVT, a finding of uncompressible popliteal or common femoral veins on compression ultrasonography can confirm the presence of residual clot and establish the diagnosis of PTS. If compression ultrasonography is normal, Doppler ultrasound to assess valve competency is indicated. If both studies

are normal, the diagnosis of PTS is unlikely, even in the presence of symptoms. Two diagnostic caveats are that the diagnosis of PTS should not be made without clinical symptoms or too soon after the acute episode of DVT, because the early associated swelling and pain of acute DVT may subside in 3 to 6 months without the development of PTS.

#### Prevention

Because recurrent ipsilateral DVT is a known risk factor for PTS, prophylaxis to prevent DVT and good anticoagulation to prevent recurrence are basic preventive measures. The appropriate duration of anticoagulation has long been in question, but a recent study suggests that an elevated D-dimer 1 month after discontinuation of oral anticoagulation is associated with an increased risk of recurrent disease (Palareti et al. N Engl J Med 2006; 355:1780). Other studies have found that elevated D-dimer levels, in association with residual thrombosis, predict recurrence. If recurrent disease can be reduced by appropriate duration of anticoagulation, such a change may also effect the development of PTS.

Other possible prophylactic measures include early mobilization after the acute episode of DVT (Partsch et al. Int Angiol 2004; 23:206) and prolonged use of compression stockings after the initial episode. Two studies have found that use of compression stockings for 2 years after the initial episode of DVT can decrease the incidence of PTS by 50% (Brandjes et al. Lancet 1997; 349:759; Prandoni et al. Ann Intern Med 2004; 141:249), although a study of compression stockings using sham compression stockings as a control found no effect of compression on the development of PTS (Ginsberg et al. Ann Intern Med 2001; 161:2105). Despite the negative findings of the only sham controlled trial, antithrombotic guidelines recommend the prolonged use of compression stockings following an acute episode of DVT (Buller et al. Chest 2004; 126(suppl):401S).

The role of thrombolytic therapy remains controversial. Thrombolysis

hastens the return of venous patency after acute DVT, but it does not clearly result in a lower incidence of PTS and is associated with a higher complication rate, mainly bleeding (Forster et al. *Curr Opin Hematol* 2002; 9:437).

#### Treatment

The treatment of PTS is even more problematic. Treatments are the same as those used for primary venous insufficiency, but they are usually less effective for PTS. Therapies include the use of compression stockings, intermittent compression pumps, leg elevation, topical treatment of ulcers, medications such as horse chestnut seed extract or hydroxyethyl rutosides, and sometimes surgery (Pesavento et al. Semin Thromb Hemost 2006; 32:744). Diuretics do not appear to be useful for the edema of PTS. In general, the prognosis is better for patients whose symptoms become worse quickly than for those whose symptoms progress more slowly.

#### What We Need To Know

We are in need of a much greater understanding of the pathophysiology and etiology of PTS.

Understanding the roles of microcirculation, inflammation, and injury in the development of this syndrome may help develop more effective treatments. More information about patients at risk may help target preventive strategies. Specific markers of disease would also be important in the diagnosis of the condition. More prospective randomized controlled trials of therapies, including thrombolytics and compression, with appropriate controls to determine best therapies, best prophylactic measures, and duration of therapies are needed. Lastly, a much greater awareness of this important cause of disability is crucial to the consistent application of currently known preventive measures. Patients also need to be aware of the syndrome and cautioned to seek help if it develops.

> Dr. Deborah Shure, Master FCCP Editor, Pulmonary Perspectives Miami, FL

**Remarks From the Editor and Deputy Editor** 

As the outgoing Editor after 15 years and Deputy Editor after 5 years, we are grateful to have shepherded *Pulmonary Perspectives* for so long and have many to thank—the past Editorial Board members, the contributors, the readers who have made such generous comments about the quality and usefulness of *Perspectives*, and, most particularly, Pam Goorsky, our in-house editor extraordinaire. Her professionalism, effectiveness, graciousness, and good humor are beyond measure. Our philosophy for *Perspectives* has been to provide opinions on interesting topics from experts in the field without the constraints of the traditional journal format. Along with our readers, we have learned a great deal with each issue. We hope that the incoming Editor and Deputy Editor will find the experience as rewarding as we have.

Dr. Deborah Shure, Master FCCP, Editor Dr. Aymarah M. Robles, FCCP, Deputy Editor

# Retek® TELITHROMYCIN tablets

#### sanofi aventis

US.TEL.06.10.046 ©2006 sanofi-aventis U.S. LLC

www.ketek.com

### **NEWS FROM THE COLLEGE**

### CRITICAL CARE COMMENTARY Status Asthmaticus in the Pediatric ICU

There are few studies that critically examine treatment of severe asthma exacerbations in the PICU.

sthma exacerbations are one of the most common causes of hospitalization in children.

Although there have been considerable advances in our understanding of its pathophysiology and an array of treatment options, asthma remains a potentially fatal disease with significant morbidity. While overall hospitalization for asthma is decreasing in children, the incidence of severe status asthmaticus requiring pediatric ICU (PICU) admission appears to be increasing.

Despite a large amount of ongoing research regarding the management of children with asthma, there are few studies that critically examine the treatment of severe asthma exacerbations in the PICU.

Large prospective clinical trials are difficult, due to the relatively small numbers of children admitted to the PICU with asthma and the wide variability in treatment practice between regions and among institutions (Bratton et al. *J Pediatr* 2005; 147:355).

As a result, treatment for refractory asthma exacerbations is generally determined by personal experience, anecdotal evidence, and the results of small clinical studies.

Defining rigorous outcome measures is also difficult in pediatric patients with asthma. Critically ill children, due to their age and developmental level, are frequently unable to reliably perform tests that are used to assess pulmonary function in adult patients with asthma exacerbations, such as spirometry and peak flow testing (van der Windt et al. *J Clin Epidemiol* 1994; 47:635).

Clinical asthma scores, derived from combinations of physical findings, have been developed in an effort to quantify severity of illness in these children. The lack of reliable and reproducible measures of pulmonary function in critically ill children is a significant barrier to clinical trials in this population.

First-line care for the treatment of pediatric asthma exacerbations includes oxygen, systemic corticosteroids, and aerosolized  $_{B2}$ -agonists. In children unresponsive to these treatments, PICU admission is necessary for additional therapies and closer monitoring of respiratory status. Several second-line therapies are available, a combination of which is used in the PICU for the treatment of status asthmaticus.

 $\beta_2$ -Adrenergic Receptor Agonists Additional  $\beta_2$ -adrenergic receptor agonists, delivered either by aerosol or IV, are frequently the next step in the treatment of pediatric status asthmaticus incompletely responsive to initial therapy. Continuously delivered albuterol is generally preferred in children and has been found to reduce hospitalizations and improve pulmonary function when compared with intermittent aerosol treatments (Ca-

Critical Care

margo et al. *Cochrane Database Syst Rev* 2003; 4:CD001115). Relatively high doses of continuous albuterol (20 to 30 mg/h) are routinely used to

treat acute bronchospasm in children, and undiluted albuterol aerosols have even been used in certain clinical situations (Gutglass et al. *Pediatrics* 2000; 105:e67). These therapies are generally well tolerated, with a minimum of cardiac side effects, in pediatric patients (Chiang et al. *J Pediatr* 2000; 137:73).

In children with severe airway obstruction, IV  $\beta_2$ -adrenergic receptor agonists are used to overcome problems with drug delivery.

Terbutaline, the only IV  $\beta_2$ -agonist available in the United States, has been shown to improve pulmonary function and gas exchange and to shorten PICU length of stay when titrated according to clinical asthma score (Carroll et al. Pediatr Pulmonol 2006; 41:350). In this prospective study, children with status asthmaticus incompletely responsive to inhaled  $\beta_2$ -agonists were treated with IV terbutaline according to a protocol that titrated the terbutaline dose based on their severity of illness. These children had significantly shorter PICU length of stay, shorter hospital length of stay, and reduced hospital charges when compared with children treated with IV terbutaline prior to initiation of the protocol. Dosing ranges of up to 4 µg/kg/min of IV terbutaline have been used in children with status asthmaticus.

#### Anticholinergics

Aerosolized anticholinergic medications, such as ipratropium, are effective bronchodilators and another mainstay in the treatment of children admitted to the PICU with status asthmaticus.

The combination of ipratropium and  $\beta_2$ -adrenergic receptor agonist therapy has been well shown to improve pulmonary function and to reduce hospitalization, with particular benefit in critically ill children (Schuh et al.

*J Pediatr* 1995; 126:639). Aerosolized ipratropium has minimal side effects at the usual dosage of 250 to 500 µg every 6 h.


#### Magnesium

Institute

American College

of Chest Physicians

The efficacy of magnesium for the treatment of children with acute asthma exacerbations is controversial. Magnesium, when delivered IV, has shown acute bronchodilatory effects and may reduce the inflammatory response in asthma. However, systematic reviews of the literature have not



sult, magnesium remains an unproven therapy in children admitted to the PICU with status asthmaticus.

#### Heliox

Heliox, a blend of helium and oxygen, reduces airway resistance and may be a therapeutic option for severe refractory asthma in children. Studies have found a reduction in dyspnea, improved gas exchange, and improved pulmonary function in some patients.

However, a randomized, controlled trial in children (Carter et al. *Chest* 1996; 109:1256) and a systematic review of the literature failed to demonstrate significant beneficial effect (Ho et al. *Chest* 2003; 123:882). In addition, to significantly lower the density of the inhaled gas, helium needs to comprise 60 to 80% of the mixture, prohibiting its use in many hypoxemic children with status asthmaticus.

#### Methylxanthines

Aminophylline and theophylline were at one time the primary therapy for acute asthma exacerbations. Recently, these medications have fallen out of favor due to their narrow therapeutic range, higher incidence of side effects, and decreased effectiveness compared with sympathomimetic therapy (McFadden et al. *Am J Respir Crit Care Med* 2003; 168:740). In the PICU, however, methylxanthines may continue to play a role in those children incompletely responsive to higher dose  $\beta_2$ adrenergic receptor agonist and anticholinergic therapy.

### Endotracheal Intubation and Mechanical Ventilation

If a patient does not respond to aggressive medical therapy, endotracheal intubation and mechanical ventilation may be necessary. However, identifying which children may benefit from mechanical ventilation is challenging.

Although potentially life-saving, endotracheal intubation and mechanical ventilation can aggravate bronchospasm, worsen underlying dynamic hyperinflation, and are associated with a relatively high incidence (10 to 26%) of serious adverse effects in children with asthma (Werner et al. *Chest* 2001; 119:1913). In addition, modest degrees of hypercarbia are generally well-tolerated in nonintubated children with status asthmaticus (Roberts et al. *Crit Care Med* 2002; 30:581).

Because of the risks involved with this intervention, aggressive medical therapy is encouraged prior to endotracheal intubation.

#### Noninvasive Positive Pressure Ventilation

The success of noninvasive positive pressure ventilation (NPPV) in treating acute exacerbations of other chronic obstructive diseases has led to the interest in the use of NPPV for the treatment of asthma.

NPPV has shown some benefit in the treatment of asthma exacerbations in adults, improving gas exchange and respiratory function in some patients (Meduri et al. Chest 1996; 110:767). In another small case series of children admitted to the PICU with status asthmaticus (Carroll et al. Ann Allergy Asthma Immunol 2006; 96:454), NPPV improved subjective and objective markers of pulmonary function and was well-tolerated for several days without the need for significant amounts of sedative medications. Staff familiarity with NPPV, combined with nonpharmacologic methods of relaxation and distraction, is important to sustain tolerance in this population.

#### Conclusion

Treatment of status asthmaticus in children admitted to the PICU is frequently subjective and includes a combination of second-line therapies. Few controlled studies that examine the efficacy of treatments received in the PICU exist and, as a result, there are few truly evidence-based treatment strategies.

Barriers to clinical trials include the relatively small numbers of children admitted to the PICU with status asthmaticus, the wide variability in treatment strategies, and lack of rigorous outcome measures. Improving outcomes in this population will require strategies to overcome these barriers in future studies.

Dr. Christopher L. Carroll, FCCP Assistant Professor, Pediatric Critical Care Connecticut Children's Medical Center Hartford, CT

#### MERICAN COLLEGE E W R 0 Μ н C LE Ν S F Ε Т 0 L G F 🙈 CHEST

### PRACTICE MANAGEMENT UPDATE **On-site Practice Management Consultations**

ome members took advantage of a new service at CHEST 2006 provided by the Practice Management Department. Diane Krier-Morrow, MBA, MPH, CCS-P, coding and reimbursement consultant to the College, provided

one-on-one consultations on any practice management issue of interest to attendees.

Twenty-five College members participated in these consultations and were pleased to speak with someone on issues

of interest to their particular practice situation. The discussions were as varied as the types of practice situations that exist. A sampling follows:

► A solo practitioner from Tennessee wanting to expand his practice.



#### 62.5 mg and 125 mg film-coated tablets

nary: Please see package insert for full prescribing information.

Use of TRACLEER® requires attention to two significant concerns: 1) potential for serious liver injury, and 2) potential damage to a fetus. 2) potential damage to a fetus. WARNING: Potential liver injury. TRACLEER\* causes at least 3-fold (upper limit of normal; ULN) elevation of liver aminotransferases (ALT and AST) in about 11% of patients, accompanied by elevated bilirubin in a small number of cases. Because these changes are a marker for potential serious liver injury, serum aminotransferase levels must be measured prior to initiation of treatment and them monthy (see WARNINGS: Potential Liver Injury and DOSAGE AND ADMINISTRATION). In the post-marketing period, in the setting of close monitoring, rare cases of unexplained hepatic cirrhosis were reported after prolonged (> 12 months) therapy with TRACLEER\* in patients with multiple co-morbidities and drug therapies. There have also been rare reports of liver failure. The contribution of TRACLEER\* in these cases could not be excluded. In at least one case the initial presentation (after > 2) months of treatment included nonpounced elevations in the latent one case the initial presentation.

In at least one case the initial presentation (after > 20 months of treatment) included pronounced elevations in aminotransferases and bilintial news accompanied by non-specific symptoms, all of which resolved slowly over time after discontinuation of TRACLEER\*. This case reinforces the importance of strict adherence to the monthly monitoring schedule for the duration of treatment and the treatment algorithm, which includes stop-ping TRACLEER\* with a rise of aminotransferases accompanied by signs or symptoms of liver dystunction (see DOSAGE AND ADMINISTRATION).

(see DOSAGE AND ADMINISTRATION). Elevations in aminotransferases require close attention (see DOSAGE AND ADMINISTRATION). TRACLEER<sup>®</sup> should generally be avoided in patients with elevated aminotransferases (> 3 x ULN) at baseline because mon-itoring liver injury may be more difficult. If liver aminotransferase elevations are accompanied by clinical symptoms of liver injury (such as nausea, vomiting, tever, abdominal pain, jaundice, or unusual lethargy or tatigue) or increases in bilinution B 2 x ULN, treatment should be stopped. There is no experience with the re-introduction of TRACLEER<sup>®</sup> in these circumstances. CONTRAINDICATION: Pregnancy. TRACLEER<sup>®</sup> (bosentan) is very likely to produce major birth defects if used by pregnant women, as this effect has been seen consistently when it is administered to animals (see CONTRAINDICATIONS). Therefore, pregnancy must be excluded before the start of treatment with TRACLEER<sup>®</sup> and prevented thereafter by the use of a reliable method of contraceptiven. Hormonal contraceptives, including oral, injectable, transdermal, and implantable contraceptives should not be used as the sole means of contra-ception because these may not be effective in patients receiving TRACLEER<sup>®</sup> (see Precautions: Drug Interactions). Therefore, effective contraception through additional forms of contraception must be practiced. Monthly pregnancy tests should be obtained.

Recause of potential liver injury and in an effort to make the chance of fetal exposure to TRACLEER\* (losentan) as small as possible, TRACLEER\* may be prescribed only through TRACLEER\* Access Program by calling 1 866 228 3546. Adverse events can also be reported directly via this number.

 Because of potential liver injury and in an effort to make the chance of fetal exposure to TRACLEER\* (losentan) as small as possible, TRACLEER\* may be prescribed only through TRACLEER\* Access Program by calling 1 866 228 3546. Adverse events can also be reported directly via this number.
 INDICATIONS AND USAGE: TRACLEER\* is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with WHO Class III or V Symptoms, to improve exercise ability and decrease the rate of clinical worsening.
 CONTRAINDICATIONS: TRACLEER\* is contraindicated in pregnancy, with concomitant use of cyclosporine A, with coadministration of glyburide, and in patients with are hypersensitive to bosentan or any component of the medication. Pregnancy Category X: TRACLEER\* is noteed to cause fetal harm if administered to pregnant women. The similarly of maformations induced by bosentan and those observed in endothelin-1 knockut mice and in animals treated with other endothelin receptor antagonists indicates that treatogenicity is a class effect of these drugs. There are no data on the use of TRACLEER\* in pregnant women. TRACLEER\* should be started only in patients known not to be pregnancy test should not be issued by the prescriber that the is not sexually active or provides negative results from a urine or serum pregnancy test should be obtained monthy in women of childbearing potential taking TRACLEER\* should be tast of the set any contrained start or serum pregnancy tests should be obtained monthy in women of childbearing potential taking TRACLEER\*. The patient must be advised that if there is any delay in onset of menses or any other reason to suspect pregnancy. He physician inmediately for pregnancy tests by potential or serum pregnancy tests by potential taking the patient instructions of 2% of placebo-treated patients (N = 280). The combination of hepatocellular injury (increases in mainotransferases elvelatin as accesse the reduced accur of % of placebo-treated patient Summer and a verses of usernant reastment. Juring the course of treatment the hemoglobin concentration remained within normal limits in 68% of bosentan-treated patients compared to 76% of placebo patients. The explanation for the change in hemoglobin is not known, but it does not appear to be hemorrhage or hemolysis. It is recommended that hemo-globin concentrations be checked after 1 and 3 months, and every 3 months thereafter. If a marked decrease in hemo-globin concentration be checked after 1 and 3 months, and every 3 months thereafter. If a marked decrease in hemo-globin concentration be checked after 1 and 3 months, and every 3 months thereafter. If a marked decrease in hemo-globin concentration cours, further evaluation should be undertaken to determine the cause and need for specific treatment. *Fluid retention*: In a placebo-controlled trial of patients with severe chronic heart failure, there was an increased incidence of hospitalization for CH sassociated with weight gain and increased leg dema during the first 4-8 weeks of treat-ment with TRACLEER\*. In addition, there have been numerous post-marketing reports of fluid retention in patients with pul-monary hypertension, occurring within weeks after starting TRACLEER\*? Patients required intervention with a diuretic, fluid management, or hospitalization for decompensating heart failure. Information for Patients: Patients are advised to consult the TRACLEER\* Medication Guide on the safe use of TRACLEER\*. The physician should discuss options for effective contraception and measures to prevent pregnancy with their female patients. Input from a gynecologist or similar expert on adequate contraception should be sought as needed. **Durg Interactions:** Bosentan is metabolized by CYPI29 and CYP304 Inhibition of these langes measures in the balance in the super-

contraception and measuries to prevent pregnancy with their female patients'. Input from a gynecologist or similar expert on adequate contraception should be sought as needed. **Drug Interactions:** Bosentan is metabolized by CYP2C9 and CYP3A4. Inhibition of these isoenzymes will likely increase the plasma concentration of bosentan. Bosentan is an inducer of CYP3A4 and CYP2C9. Consequently, plasma concentrations of drugs metabolized by these two isoenzymes will be decreased when TRACLERF' is co-administred. Contraceptives: Co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum® produced decreases of norethindrone and ethinyl estradiol levels by as much as 56% and 66%, respectively, in individual subjects. Therefore, hormonal contraceptives, including oral, injectable, transformal, and implantable forms, may not be reliable when TRACLERF' is co-administered. Women should practice additional methods of contraception and not rely on hormonal contraception alone when taking TRALCLERF'. Cyclosporine A Lives CONTRAINDIGATIONS). Tacrolinus: Co-administration, trough con-centrations of bosentan were increased by about 30-fold. Steady-state bosentan plasma concentrations were a to 4-fold higher than in the absence of cyclosporine A Lives CONTRAINDIGATIONS). Tacrolinus: Co-administration of tacrolinus and bosentan has not been studied in man. Co-administration of tacrolinus and bosentan resultied in markedly increased plasma concentrations of obsentan in animals. Caution should be exercised if tacrolinus and bosentan are used together. Glyburide: An increased risk of elevated liver aminotransferases was observed in patients receiving concomitant therapy with glyburide (see CUNTRAINDICATIONS). Tacrole tycr3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold. No dose adjustment of bosentan is necessary, but increased the plasma concentrations of ismvastatin (a CYP3A4, substrate), and its active 6-hydroxy acid metabolite, by approximately 50%. The plasma

should be considered. Patients using CYP2A4 metabolized stains should have cholesterol levels monitored after TRACLEER\* is initiated to see whether the stain dose meds adjustment. Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2AS substrate) and R-warfarin (a CyP2AS substrate) by 28 and 38%, respectively. Clinical experience with concomitant administration of bosentan in 60 warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose, and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan - and placebo-treated patients. Digoxin, Nimodipine and Losartan: Dosentan Inas been shown to have no pharmaco-kinetic interactions with digoxin and immofpine, and losartan ihas no effect on plasma levels of losentan.
 Sidenafit In healthy subjects, co-administration of multiple doses of 125 mg b.id. Bosentan and Bomg t.id. silenafil resulted in a reduction of sildenafil plasma concentrations by 50%. A dose djustment of neither drug is necessary. This recommendation holds true when sildenafil is used for the treatment of pulmonary arterial hypertension or erectile dysfunction.
 Carcinogenesis, Mutagenesis, Impairment of Ferlility: Two years of dietary administration of bosentan to mice produced an increased incidence of colon adenomas in both males and females. In rats, dietary administration of bosentan for two years was associated with an increased incidence of colon adenomas in both males and females. In rats, dietary administration of bosentan for two years was associated with an increased incidence of the same produced by and decreases in male ferlility firstwhen administered for longer than 10 weeks. Where studie, lesticular tubular atrophy was observed in male male male males at doses about 8 times the MRHD ore to generating in the testes and to raduce spare nounds and

representatives, reach angrouena. Special Considerations: Patients with Congestive Heart Failure (CHF): Based on the results of a pair of studies with 1613 subjects, bosentan is not effective in the treatment of CHF with left ventricular dysfunction.

subjects, bosentan is not effective in the treatment of CHF with left ventricular dysfunction. **OVERDOSAGE:** Bosentan has been given as a single dose of up to 2400 mg in normal volunteers, or up to 2000 mg/day for 2 months in patients, without any major clinical consequences. The most common side effect was headache of mild to moderate intensity. In the cyclosporine A interaction study, in which doses of 500 and 1000 mg b.i.d. of bosentan were given concomitantly with cyclosporine A, trough plasma concentrations of bosentan increases do 1000, resulting in severe headache, nauces, and vomiting, but no serious adverse events. Mild decreases in blood pressure and increases in heart rate were observed. There is no specific experience of overdosage with bosentan beyond the doses described above. Massive overdosage may result in pronounced hypotension requiring active cardiovascular support. **DOSAGE AND ADMINISTRATION**: TRACLEER\* treatment should be initiated at a dose of 62.5 mg b.i.d. for 4 weeks and then increased to the maintenance dose of 125 mg b.i.d. Joses above 125 mg b.i.d. did not appear to confer additional benefits ufficient to offset the increased risk of liver injury. Tablets should be administered morning and evening with or without food.

age Adiu tment and Monitoring in Patients Developing Aminotransferase Abnormalities

ALT/AST levels	Treatment and monitoring recommendations
> 3 and A5 x ULN	Confirm by another aminotransferase test, if confirmed, reduce the daily dose or interrupt treatment, and monitor aminotransferase levels at least every 2 weeks. If the aminotransferase levels return to pre-treatment values, continue or re-introduce the treatment as appropriate (see below).
> 5 and A8 x ULN	Confirm by another aminotransferase test; if confirmed, stop treatment and monitor aminotransferase levels at least every 2 weeks. Once the aminotransferase levels return to pre-treatment values, consider re-introduction of the treatment (see below).
> 8 x ULN	Treatment should be stopped and reintroduction of TRACLEER® should not be considered. There is no experience with re-introduction of TRACLEER® in these circumstances.
TDACLEED® in un internal	والمرابق والمراجع والمراجع والمراجع والمراجع والمراجع والمحمد والمراجع والمراجع والمراجع والمراجع والمراجع والم

There is no experience with reintroduction of TRACLEER' in Modulated within a set of the set o

Rx only.

STORAGE: Store at 20°C – 25°C (68°F – 77°F). Excursions are permitted between 15°C and 30°C (59°F and 86°F). [See USP Controlled Boom Temperature]

Reference for previous pages: 1. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenge syndrome: a multicenter, double-blind, randomized, placebo-controlled study. *Circulation*. 2006;114:48–54. 2. Data on file

#### To learn more: Call 1-866-228-3546 or visit www.TRACLEER.com

Manufactured by: Patheon Inc. Mississauga, Ontario, CANADA



© 2006 Actelion Pharmaceuticals US, Inc. All rights reserved. 06 097 01 00 0906

pulmonary and sleep medicine, a couple years before retirement, wanting to revise his templates for evaluation and management coding with discussion of patient history documentation, promised to develop a practice compliance plan. ► A cardiothoracic surgeon from Georgia who had not looked at his surgical payments on selected procedures in years and was concerned with the significant drop in payments. Relevant CPT thoracoscopy codes on AMA's Code-Manager were reviewed, and it was explained that nationally, ACCP represents pulmonary, critical care, and sleep medicine through the AMA CPT and RUC processes. He was referred to the Society of Thoracic Surgeons, which represents him nationally on coding and reimbursement issues. There is a thoracic surgery chapter in the new ACCP 2007 coding book.

A California physician in

A number of physicians from the Private Practice Leadership Program were interested in talking individually about the new 2007 diagnostic and procedure codes presented at their Saturday session. ► Two pediatric pulmonologists

were very interested in talking about the new sleep apnea codes, CPT 94774-94777.

A fellow stopped by to ask some basic coding questions, such as what is ICD-9-CM diagnostic and CPT procedural coding. Diane spoke with the Private Practice Net-Work and suggested that a program be developed for fellows before they begin their practices. This is being investigated for CHEST 2007.

Check the 2007 edition of Appropriate Coding for Critical Care Services and Pulmonary Medicine for details on the new procedure and service codes.

Most importantly, there are new ventilation management codes, 94002-94005 for CPT 2007. Also. the 6-minute walk test and oximetry were added to the parenthetical for simple pulmonary stress testing in CPT 94620.

In the allergy section, a new code for expired nitric oxide is 95012. We believe that this PFT will require modifier 25 on the evaluation management service if provided on the same day, because that code is in the allergy section of CPT.

There are new sleep apnea codes, CPT 94774-94777. Additionally, there is a new code for surfactant administration, 94610 and **99363-4** for anticoagulant.

#### CHEST

#### н Ε E R 0 0 W S F Μ Ε L Ε Ν G **NETWORKS Two New Guidelines Being Produced**

www.chestnet.org/network

### Pulmonary Physiology, Function, and Rehabilitation

Two years ago, the Pulmonary Function, Physiology, and Rehabilitation NetWork began work on an update of the 1997 Evidence-Based Guidelines for Pulmonary Rehabilitation.

Several members of the ACCP were selected by the Health and Science Policy Committee and appointed by the College to work with several members of the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) on the project. The committee worked with Carla Herrerias, ACCP Clinical Research Analyst, to research the literature and put together the updated version of the guidelines. The newly developed ACCP grading system for guidelines was used in the process (*Chest* 2006; 129:174-181).

The document is in its final draft form and is undergoing review by the AACVPR and the ACCP boards for suggestions and final approval.

The updated version of the guidelines evaluated those topics reviewed in the 1997 guidelines, including various components (*eg*, lower and upper extremity training, inspiratory muscle training) and outcomes (*eg*, dyspnea, health-related quality of life, health-

care utilization) associated with pulmonary rehabilitation. In the updated version, there was also evaluation of other components associated with rehabilitation, including psychosocial intervention; longterm maintenance; nutrition; rehabilitation for diseases other than COPD; and adjunctive therapies, including supplemental oxygen therapy and anabolic steroids.

This project involved the collaboration of two organizations that are intimately involved in providing pulmonary rehabilitation for patients

with chronic lung disease and should help us optimize provisions of rehabilitative services for patients.

#### **Thoracic Oncology**

More than 50 Thoracic Oncology Net-Work members serve on the panel that has been actively describing the evidence and developing recommendations for the Diagnosis and Management of Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition).

Additional members were recently involved in reviewing chapters from these guidelines, which are expected to be published in 2007.

The primary focus of the NetWork in the next year will be the promotion of the guidelines through programs and sessions at CHEST 2007, development of implementation tools, and other marketing efforts.

Also, watch for the debut of the new Web pages for this NetWork. The Web pages will feature clinical content, NetWork projects, and other NetWork activities.

For further information or to learn more about the Thoracic Oncology NetWork, contact Sandra Zelman Lewis, PhD, staff liaison, via e-mail at slewis@chestnet.org.

#### **Clinical Pulmonary Updates...Sized for Kids**



### CELEBRATION OF PEDIATRIC PULMONOLOGY 2007

March 16 - 18 San Antonio, Texas

Co-Chairs LeRoy Graham, MD, FCCP Dennis Gurwitz, MB, BCh, FAAP Pedro Mayol, MD, FCCP

Plan now to attend this state-of-the-art update in clinical pediatric pulmonology to hear the latest research findings for topics in pulmonology, infectious disease, radiology, and surgery.

Designed to promote interaction between you and the renowned faculty, this course will allow you to:

- Hear recent clinical updates related to pediatric lung disease.
- Participate in interactive discussions and hands-on workshops with experts in the field.
- Ask questions about issues specifically impacting your practice.

American Academy of Pediatrics

Register Early and Save Register by February 16 for an early registration discount. www.chestnet.org (800) 343-2227 or (847) 498-1400

• CHEST

### Specialty Medicine. Specialty Codes.



#### New! 11th Edition Includes 7 New Chapters

For a coding resource as precise and specialized as the medicine you practice, turn to Appropriate Coding for Critical Care Services and Pulmonary Medicine 2007. Features detailed coding information for critical care, consultations, pulmonary function testing, bronchoscopy, ICU procedures, and pulmonary rehabilitation, as well as vital information about managing your practice. New chapters include coding anesthesia services and moderate sedation, thoracic surgical procedures, electronic medical records, pay for performance, and malpractice issues.

Member \$125 Nonmember \$160 Product #1269

Reserve your copies today. www.chestnet.org (800) 343-2227 or (847) 498-1400



#### 18

#### Ε W S Μ Π Ε C 0 CHEST

### Happy 10th Birthday to NLHEP!

BY DENNIS E. DOHERTY, MD, FCCP Chairman of NLHEP AND GRETCHEN LAWRENCE, BA, RRT Program Associate for NLHEP

s a result of a pivotal meeting on the state of COPD in 1996, the National Lung Health Education Program (NLHEP) was created.1 Goals for the organization have not changed: to increase awareness of COPD to the community and to health-care professionals; and to support the use of spirometry in the primary care physician (PCP) office to establish an earlier diagnosis of this under-appreciated disease.

Educational materials have been developed and revised over the past 10 years, among them "Save Your Breath America," a booklet written in easy-tounderstand language for COPD patients and their families.

A new professional booklet, "Long

Term Oxygen Therapy: History, Scientific Foundations, and Emerging Technologies," a product of the 6th Oxygen Consensus Conference, was released in October.

In the past 2 months, over 10,000 of these two book-

lets alone have been distributed in time for Respiratory Care Week and National COPD Month. The battle cry of NLHEP, "Test Your Lungs-

Know Your Num-

bers," emphasizes earlier detection of COPD via routine use of spirometry in primary care offices.

This concept was reinforced in 2004 when NLHEP launched the Spirometer Review Process (SRP)-an evidence-based evaluation tool using a list of required features that are easy for manufacturers to incorporate into

their office spirometry systems-and make it easier for PCPs to use these simple devices to obtain the only three numbers needed to make the diagnosis of COPD, the FEV<sub>1</sub> and FEV<sub>6</sub> expressed as a percent of predicted

(based on age, height, and gen-

**A REVIEW OF NLHEP'S EFFORTS** der), and the  $FEV_1/FEV_6$ **CLEARLY SHOWS THAT THIS** ratio.2 **ORGANIZATION IS AS DEDICATED** The most re-

cent addition to NLHEP's educational arsenal are the COPD awareness posters, with

all 13 available now in Spanish.

These colorful posters represent all ages, ethnic groups, and both genders and are intended for display where patients go for health care-the PCP office, the ED, outpatient clinics, and health fairs. These posters and much more information can be found on the NLHEP Web site (www.nlhep.org).

NLHEP turns 10 this year, and a review of its efforts clearly shows that this organization is as dedicated to its goals as it was when it was formed 10 years ago—and NLHEP continues to be an active participant in the fight to increase awareness of COPD across the United States.

Several ACCP Fellows serve on the Executive Board, and Dr. Robert M. Rogers, FCCP, is the ACCP representative to the board.

#### References

1. Petty TL, Weinmann GG. Building a national strategy for the prevention, management, and research in chronic obstructive pulmonary disease. JAMA 1997; 277:246-252

2. Ferguson GT, Enright PL, Buist AS, et al. Office spirometry for lung health assessment in adults: a consensus statement for the National Lung Health Education Program. Chest 2000; 117:1146-1161

### **CLASSIFIEDS**


TO ITS GOALS AS IT WAS WHEN

**IT FORMED 10 YEARS AGO.** 

#### **PROFESSIONAL OPPORTUNITIES**



Straub Clinic & Hospital, 150-physician multi-specialty group with a 159-bed hospital, is seeking a fellowship trained BC pulmonologist with expertise in pulmonary hypertension, interstitial lung disease, and interventional bronchoscopy. This out-patient based position in our Chest Diseases Clinic is at the same location as our hospital for in-patient care. Straub is part of Hawaii Pacific Health, one of the largest healthcare systems in the state, providing tertiary, specialty, and acute care services. Benefits include relocation allowance and professional liability insurance. Combine a professional career with the recreational activities, cultural diversity, superb lifestyle and excellent climate year-round. Visit www.straubhealth.org Send CV to: Ellen Kaye, Physician Recruitment Coordinator, Straub Clinic & Hospital, 888 South King Street, Honolulu, HI 96813; email ekave@straub.net fax: (808) 522-4006; phone: (800) 5-STRAUB (578-7282



We are seeking Intensivists to join our 200-physician, multi-specialty group at Southwest Medical Associates in Las Vegas.

We are a subsidiary of Sierra Health Services (NYSE–SIE) and affiliated with Health Plan of Nevada.

#### SMA IS OFFERING:

- 100% Critical Care Leapfrog program
  - 6 & 12 hour in-house shifts 9 bed closed unit
  - 4 days on/2 days off
  - 10 (24 hour) blocks off time per month

 Comprehensive benefits including Health, Dental, Life, Disability, Malpractice insurance, matching 401K

Contact Marci Jackson (702) 326-3508 MJackson2@sierrahealth.com www.smalv.com or www.sierrahealth.com

#### $\langle \otimes \rangle$

SOUTHWEST MEDICAL ASSOCIATES, INC.

Call Rhonda Beamer 443-512-8899 Ext 106 for more information.

#### Marietta Pulmonary Medicine Suburban Atlanta

Well-established, busy 11-physician single-specialty Pulmonary practice in suburban At-lanta, Georgia, looking for one or more BC/BE Pulmonary/Critical Care physicians. Sleep certification is a plus. Practice includes all aspects of pulmonary medicine, includ-ing critical care, sleep medicine, out-patient clinic, pulmonary rehab and clinical research. Practice located at one large acute-care hospital, with the busiest ER in Georgia, and also rounds at a near-by long term acute care hospital. Installation of an electronic ICU monitoring system planned for the near future. Competitive salary with bonus potential and generous benefits package. Please fax CV to 770-792-1738.

#### **PULMONARY**/ **CRITICAL CARE FACULTY**

Additional pulmonary/critical care faculty members are sought for a growing section at Washington Hospital Center. WHC is a 907-bed not-for-profit teaching hospital located in downtown Washington, DC. The pulmonary/critical care section is responsible for a busy ICU, IMC, inpatient and out-patient consultation service, and respiratory therapy. An integrated pulmonary/critical care fellowship program has been developed with NIH. In addition to clinical and teaching responsibilities an interest in research is expected. Address inquiries, along with CV, to Gene Colice, MD, Director, Section of Pulmonary, Critical Care & Respiratory Services, Washington Hospital Center, 110 Irving Street, NW, Room 2A68; Tel #202-877-7856; Fax #202-291-0386.

#### Disclaimer

CHEST PHYSICIAN assumes the statements made in classified advertisements are accurate, but cannot investigate the statements and assumes no responsibility or liability concerning their content. The Publisher reserves the right to decline, withdraw, or edit advertisements. Every effort will be made to avoid mistakes, but responsibility cannot be accepted for clerical or printer errors

Have questions on classifieds?

### Parents and Children Disagree on Asthma Impact

BY JANE SALODOF MACNEIL Elsevier Global Medical News

SAN FRANCISCO — A physician who relies on parent reports to assess the effects of asthma on a child's physical and emotional health may be getting only part of the story, according to findings presented in a poster at the annual meeting of the Pediatric Academic Societies.

Separate interviews with 414 children (aged 7-16 years) and one of their parents showed that parents and children often disagree about the impact of asthma, sociologist Lynn M. Olson, Ph.D., reported.

Dr. Olson, director of the department of research at the American Academy of Pediatrics in Elk Grove Village, Ill., found that children in all age groups tended to describe their physical health as worse than was reported in their parents' accounts.

"We found in each of the age groups, children were more likely to report more symptoms and worse health than did the parents," she said in an interview at the meeting, which was sponsored by the American Pediatric Society, Society for Pediatric Research, Ambulatory Pediatric Association, and American Academy of Pediatrics.

On questions of emotional health, however, adolescents were significantly less likely than parents to report a negative impact.

Dr. Olson said the study was part of a larger investigation sponsored by the National Heart, Lung, and Blood Institute that looked into children's ability to report on their own asthma health status.

Most children in the study, 61%, used a prescribed controller of asthma symptoms 5 or more days a week. Some 53% of parents described their child's condition as "moderate/severe." The population was diverse (including 46% African American, 37% white, and 11% Hispanic families), with 42% of family incomes less than \$30,000 annually.

Each parent-and-child pair completed adult and child versions of the Child Health Survey for Asthma. The survey contained questions about physical activities and asthma impact during the previous 2 weeks. Answers were computed in scores of 1-100, with higher scores signaling better health.

Under physical health, only 70% of parents and children agreed on whether the child had difficulty sleeping. Agreement was little better for questions relating to cough (73%), limits on strenuous activities (73%), and limits on sports/running outside (78%).

Agreement improved slightly when the pairs were asked about wheezing with a cold (80%), wheezing without a cold (81%), cold won't go away (81%), shortness of breath (82%), tight chest (83%), limits on moderate activities (83%), and limits in gym class (86%).

Parents and children were most likely to agree on asthma's impact on limits on mild activities (93%). They disagreed more, however, on emotional impact issues.

The lowest level of agreement, 69%, regarded frustration with asthma treatments and frustration with activity limits. Just 70% concurred when asked about the child being frustrated with having asthma and asthma causing family stress.

When Dr. Olson and her coinvestigators stratified the direction of difference by age group, children aged 7-9 years reported lower scores overall than did the parents (79.5 vs. 83.3 for physical health and 73.1 vs. 77.3 for emotional health). These differences were not statistically significant, however.

Children aged 10-12 years reported significantly worse scores for physical health, compared with their parents (80.5 vs. 86.2), but there was a trend to better child scores for emotional health (80.6 vs. 78.8) in this age group.

Adolescents aged 13-16 years reported an overall score of 77.3 for physical health, while their parents scored them at 83.7. They rated their emotional health at 79.3, but their parents gave this the lowest score: 69.1. Both differences were significant.

"When you look at the way questions are asked [and] messages are delivered, the target audience is the parent. Rarely is the audience considered to be the child," she said. "Whenever possible in research and in practice, we should be considering asking both the parents and the child."

**Dr. LeRoy M. Graham, FCCP, comments:** Specific inquiry of children regarding disease impact is an important component of clinical assessment in determining disease severity and in the formulation of effective management plans. As many, if not most, children are directly responsible for taking their medications, such inquiry may enhance adherence by establishing relevant goals of therapy.



# Help us explore the way we look at idiopathic pulmonary fibrosis (IPF)

IPF has been associated with increased levels of endothelin (ET), a 21–amino acid peptide with diverse biological functions and pathological effects.<sup>1</sup> Patients with IPF demonstrate elevated ET plasma concentrations and ET expression in the lung tissue,<sup>2</sup> and ET concentration has been found to correlate with disease activity.<sup>3</sup> Through on-going research we are exploring the link between ET and the disease of IPF.



### **Sleep-Related Breathing Disorder, Depression Linked**

**BY DIANA MAHONEY** Elsevier Global Medical News

ndividuals with sleep-related breathing disorder are at an increased risk for developing depression, and the likelihood of developing depression is directly related to the severity of the breathing disorder, a longitudinal study has demonstrated.

Because sleep-related breathing disorder and depression have both been independently associated with substantial morbidity, impairment, and disability, Paul E. Peppard, Ph.D., and his colleagues at the University of Wisconsin, Madison, designed a population-based epidemiological study to look for a link between the two conditions.

The investigators evaluated 788 men and 620 women participating in the ongoing Wisconsin Sleep Cohort Study.

All of the patients underwent between one and four overnight in-laboratory polysomnography evaluations and clinical assessments that included body mass index, medical history, and interviews to determine the nature and frequency of sleep problems, daily activities, and medication use (Arch. Intern. Med. 2006;166: 1709-15).

All of the participants completed the 20-item self-reporting Zung depression scale to assess depressive symptoms.

The scale ranges from 25 to 100; scores between 50 and 59 indicate mild depression, and scores of 60 or higher indicate moderate to severe depression.

Two sleep-related items on the Zung

## A landmark IPF morbidity and mortality trial is under way

Patients are now enrolling in a new IPF trial called BUILD-3.

Inclusion criteria include age over 18 years, biopsy-proven IPF diagnosis, and disease duration less than 3 years. Exclusion criteria include interstitial lung disease due to conditions other than IPF, and severe restrictive lung disease.

Visit www.BUILD-3.com to find the trial site nearest to your practice.

### **Refer patients - Enroll patients - Build the future**

Visit www.BUILD-3.com or www.clinicaltrials.gov to learn more. (Identifier # NCT00391443)



1. Fagan KA, McMurtry IF, Rodman DM. Role of endothelin-1 in lung disease. *Respir Res.* 2001;2:90–101. 2. Uguccioni M, Pulsatelli L, Grigolo B, et al. Endothelin-1 in idiopathic pulmonary fibrosis. *J Clin Pathol.* 1995;48:330–334. 3. Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. *Lancet.* 1993;341:1550–1554. © 2006 Actelion Pharmaceuticals US, Inc. All rights reserved. 06 174 01 01 1006

scale—"I have trouble sleeping through the night" and "I get tired for no reason"—were excluded because of their potential for creating an inherent association between sleep-related breathing disorder and depression, according to the authors.

For the investigation, the severity of sleep-related breathing disorder was categorized based on apnea-hypopnea index (AHI) cutoff points.

No events in 1 hour indicated no sleeprelated breathing disorder, 1-4 events indicated minimal sleep-related breathing disorder, 5-14 events indicated mild sleeprelated breathing disorder, and 15 or more events indicated moderate or worse sleeprelated breathing disorder.

After investigators had controlled for age, body mass index, alcoholic drink consumption, and history of cardiovascular disease, an increase in sleep-relat-

CLINICIANS SHOULD BE AWARE OF THE INCREASED LIKELIHOOD OF THE CO-OCCURRENCE OF THE TWO CONDITIONS.

ed breathing disorder level to the next higher category was associated with a 1.8-fold increase in the odds for developing depression, compared with an unchanged sleep-related breathing disorder level.

The odds of developing depression for participants with minimal, mild, or moderate or worse sleep-related breathing disorder, compared with participants who had no sleep-related breathing disorder, were 1.6-fold, twofold, and 2.6-fold greater, respectively, in adjusted models that combined longitudinal and crosssectional associations.

Further adjustments for symptoms of sleep-related breathing disorder—including insomnia, daytime sleepiness, fatigue, and polysomnographic features such as sleep efficiency and percentage of time in slow-wave sleep—did not alter the associations.

That suggests that these items are not strong explanatory factors.

The use of hypnotic agents or benzodiazepines, or the presence of comorbid conditions such as diabetes also did not alter the associations.

In addition, there was no evidence of important interactions between sleep-related breathing disorder, depression, gender, age, or comorbid conditions.

Given the association of sleep-related breathing disorder with depression, clinicians should be aware of the increased likelihood of the co-occurrence of these two conditions in patients diagnosed with either condition independently.

In addition, suboptimal mental health should be added to the list of potential multiple adverse outcomes associated with sleep-related breathing disorder.

In addition, patients should be evaluated and treated accordingly, the authors wrote.

### **Video-Assisted Thorascopic Surgery Cuts Pneumonia**

BY MITCHEL L. ZOLER Elsevier Global Medical News

CHICAGO — Video-assisted thorascopic surgery was associated with a lower risk of pneumonia compared with conventional thoracotomy for patients undergoing lobectomy, according to a review of 147 patients with non–small-cell lung cancer.

Until now, video-assisted thorascopic surgery (VATS) has had questionable value compared with open thoracotomy, but the new findings indicate that VATS causes less morbidity than does conventional surgery, Dr. Bryan Whitson said at the annual clinical congress of the American College of Surgeons.

All other outcomes were roughly similar between the two methods.

The study reviewed patients who underwent lobectomy for clinical stage I non–small-cell lung cancer at the University of Minnesota, Minneapolis, from January 1998 to June 2005. Thoracotomy was used exclusively until 2001, when VATS was introduced. Both methods were used while VATS was introduced, said Dr. Whitson, a surgeon at the university.

The review included 88 patients treated by thoracotomy and 59 treated with VATS. In general, the two groups were similar with respect to age, gender, and incidence of comorbidities such as diabetes, coronary disease, and chronic obstructive pulmonary disease. The VATS patients had a significantly higher prevalence of hypertension, chronic renal insufficiency, and history of other cancers at the time of their surgery. Pathologic




The VATS technique uses a minimal access incision. At right is the video camera.

staging during surgery showed that 92% of the VATS group and 83% of the thoracotomy group actually had stage I disease.

The only notable difference in outcomes between the two groups was in the incidence of pneumonia during the 30 days after surgery: 19.3% in the thoracotomy patients compared with 3.4% in the VATS patients, a significant difference, Dr. Whitson said.

Patients treated with VATS showed a trend toward a shorter hospital stay than did the thoracotomy patients (mean 6.4 days vs. 7.7 days), as well as a slightly longer intensive care stay (1.2 days vs. 0.5 days).

Other measures were similar, including the incidence of postoperative myocardial infarction, incidence



Traditional thoracotomy resulted in a six times higher incidence of pneumonia than the VATS technique.

of reoperations, and total survival. At an average of 4 years after surgery, the survival rate was 72% for the VATS group and 66% for the thoracotomy group.

VATS is taking off as an alternative to thoracotomy, commented Dr. Zane Hammoud, a surgeon at Indiana University in Indianapolis. But surgeons are still looking for the right indications, he added.

**Dr. Robert Cerfolio, FCCP, comments:** Although some argue that the oncologic effectiveness of VATS remains unproven, there is clearly a trend toward performing VATS lobectomy for patients with non–small-cell lung cancer. This article provides further evidence for its continued use in properly selected patients.

IT'S ALL HERE

THE BEST UPDATES ON THE SCIENCE AND BUSINESS OF SLEEP MEDICINE

2007

JANUARY 18-21

COURSE CHAIR:

DOUBLETREE PARADISE VALLEY RESORT SCOTTSDALE, AZ

JAMES M. PARISH, MD, FCCP



### Missed a Session at CHEST 2006?

Hear select sessions from CHEST 2006 with audio CDs recorded live during the meeting. Whether you missed a session or simply want to hear one again, these comprehensive CDs can deliver the information at your convenience. Satellite symposia, postgraduate courses, and general sessions are available for purchase now.

#### **Order Today**

www.chestnet.org (800) 343-2227 or (847) 498-1400

> CHEST y s 1 c 1 a N s CONTENT MANAGEMENT Corp.



Sleep Institute

Attend this 4-day review of recent developments and updates in clinical sleep medicine. Designed for practicing chest medicine professionals, Sleep Medicine 2007 will provide practical instruction on how to administer exceptional patient care and practice management techniques.

Science-related topics include sleep apnea, narcolepsy, restless legs syndrome, insomnia, parasomnias, circadian rhythm disorders, and more.

A sample of business-related topics includes coding and reimbursement, as well as ethical and legal issues affecting sleep medicine.

Hands-on polysomnography workshops will enhance your skills and offer new information you can use in your daily practice.

Learn more or register: www.chestnet.org (800) 343-2227 or (847) 498-1400

### **New NCQA Measures to Focus on Quality of Care**

**BY JANE ANDERSON** Elsevier Global Medical News

he National Committee for Quality Assurance is finalizing new performance measures that will look at quality of care all the way down to the physician group and even the individual physician level.

The measures, which will form the foundation of a new Health Employer Data and Information Set (HEDIS), could require physicians to begin reporting some quality data to health plans directly.

The draft ambulatory care quality measures were released for public comment in October. Final measures are expected before the end of the year, according to an NCQA spokesman.

"This is a big change," said Dr. Bruce Bagley, medical director for quality improvement at the American Academy of Family Physicians (AAFP) and a member of the NCQA committee that approved the draft measures. "Physicians now will begin to report some data from their clinical records, such as 'Why I didn't give an indicated medication.'"

HEDIS, which measures quality of care, is the main tool that health plans use to track and report on their performance to payers.

Until now, HEDIS has used administrative claims data "almost exclusively" to measure quality at the health plan level, said Dr. Bagley. Now, "NCQA has rewritten these specifications so that it's possible to drive the measures down to the physician level."

The draft measures are designed to allow health plans to report on physician performance for their networks. They include six prevention measures, such as breast cancer screening and influenza vaccination rates, as well as measures that address care for coronary artery disease, depression, and asthma. Measures addressing overuse and misuse of health care services also are part of the proposed HEDIS addition.

The measures include detailed technical specifications and implementation methods, such as appropriate sample sizing, for use by health plans.

The draft measures are not new, Dr. Bagley pointed out. They were included in the National Quality Forum–endorsed National Voluntary Consensus Standards for Physician-Focused Ambulatory Care, and the AQA (formerly the Ambulatory Care



Tracleer Corporate	8a-8b, 16a-16b, 17 20-21
Apple Computer Inc. Corporate	7
InterMune, Inc. Corporate	12-13
<b>Pfizer Inc.</b> Chantix	3-6
Sanofi-Aventis Ketek	15
<b>ZLB Behring LLC</b> Zemaira	23-24

Quality Alliance) adopted these measures as part of its Recommended Starter Set of Clinical Performance Measures for Ambulatory Care.

"We see these [measures] as supplementing a number of national and regional physician-level measurement efforts that are already underway," said NCQA spokesman Jeff Van Ness. Because NCQA included detailed instructions for implementation, "this lowers the hurdle for plans to begin to move and implement these among physicians," he said. Nonetheless, Dr. Bagley said, once these measures are made part of HEDIS, physician groups and individual physicians will need to develop methods to collect the necessary information without resorting to retrospective chart audits.

"We're promoting prospective data collection," such as checklists that can be filled out at the time of the patient visit, he said.

Mr. Van Ness said that most of the comments NCQA has collected on the draft measures have come from large national health plans. He declined to provide information on the content of the comments, citing privacy concerns.

**Dr. Michael Baumann, FCCP, comments:** The development and dissemination of performance measures for the outpatient and inpatient arena are an area physicians must continue to watch closely. There may be many unintended consequences that need to be monitored more closely in order to provide a fair and equitable process for physicians while continuing to improve care for our patients.

References: 1. Prolastin\* Alpha;-Proteinase Inhibitor (Human), Full Prescribing Information, January 2005. 2. Aralast" Alpha;-Proteinase Inhibitor (Human), Full Prescribing Information, August 2005. 3. Data on file, ZLB Behring LLC.

#### BRIEF SUMMARY OF PRESCRIBING INFORMATION Alpha<sub>1</sub>-Proteinase Inhibitor (Human) Zemaira<sup>®</sup>

Manufactured by: **ZLB Behring LLC** Kankakee, IL 60901 USA US License No. 1709

#### ZLB Behring

 ${
m R}$  only

Before prescribing please consult full prescribing information, a brief summary of which follows:

#### INDICATIONS AND USAGE

Alpha<sub>1</sub>-Proteinase Inhibitor (Human), Zemaira<sup>®</sup>, is indicated for chronic augmentation and maintenance therapy in individuals with alpha<sub>1</sub>-proteinase inhibitor (A<sub>1</sub>-PI) deficiency and clinical evidence of emphysema.

Zemaira® increases antigenic and functional (ANEC) serum levels and lung epithelial lining fluid levels of  $A_1\text{-}PI.$ 

Clinical data demonstrating the long-term effects of chronic augmentation therapy of individuals with Zemaira® are not available.

Safety and effectiveness in pediatric patients have not been established.

Zemaira<sup>®</sup> is not indicated as therapy for lung disease patients in whom severe congenital  $A_1\mbox{-PI}$  deficiency has not been established.

#### CONTRAINDICATIONS

Zemaira® is contraindicated in individuals with a known hypersensitivity to any of its components. Zemaira® is also contraindicated in individuals with a history of anaphylaxis or severe systemic response to A<sub>1</sub>-PI products.

Individuals with selective IgA deficiencies who have known antibodies against IgA (anti-IgA antibodies) should not receive Zemaira<sup>®</sup>, since these patients may experience severe reactions, including anaphylaxis, to IgA that may be present in Zemaira<sup>®</sup>.

#### WARNINGS

Zemaira® is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, that can cause disease. Because Zemaira® is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically the Creutzfeldt-Jakob disease (CJD) agent. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses during manufacture. (See **DESCRIPTION** section of full prescribing information for viral reduction measures.) The manufacturing procedure for Zemaira® includes processing steps designed to reduce further the risk of viral transmission. Stringent procedures utilized at plasma collection centers, plasma testing laboratories, and fractionation facilities are designed to reduce the risk of viral transmission. Stringent procedures utilized at plasma collection procedures used in the manufacture of Zemaira® also potentially provide viral reduction. Despite these measures, such products may still potentially contain human pathogenic agents, including those not yet known or identified. Thus, the risk of transmission of infectious agents can not be totally eliminated. Any infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to ZLB Behring at 800-504-5434. The physician should discuss the risks and benefits of this product with the patient.

Individuals who receive infusions of blood or plasma products may develop signs and/or symptoms of some viral infections (see **Information For Patients**).

During clinical studies, no cases of hepatitis A, B, C, or HIV viral infections were reported with the use of Zemaira $^{\circ}$ .

#### PRECAUTIONS

**General** – Infusion rates and the patient's clinical state should be monitored closely during infusion. The patient should be observed for signs of infusion-related reactions.

As with any colloid solution, there may be an increase in plasma volume following intravenous administration of Zemaira<sup>®</sup>. Caution should therefore be used in patients at risk for circulatory overload.

**Information For Patients** – Patients should be informed of the early signs of hypersensitivity reactions including hives, generalized urticaria, tightness of the chest, dyspnea, wheezing, faintness, hypotension, and anaphylaxis. Patients should be advised to discontinue use of the product and contact their physician and/or seek immediate emergency care, depending on the severity of the reaction, if these symptoms occur.

As with all plasma-derived products, some viruses, such as parvovirus B19, are particularly difficult to remove or inactivate at this time. Parvovirus B19 may most seriously affect pregnant women and immune-compromised individuals. Symptoms of parvovirus B19 include fever, drowsiness, chills, and runny nose followed two weeks later by a rash and joint pain. Patients should be encouraged to consult their physician if such symptoms occur.

© 2006 ZLB Behring LLC • 1020 First Avenue, PO Box 61501, King of Prussia, PA 19406-0901, USA • www.ZLBBehring-US.com

**Pregnancy Category C** – Animal reproduction studies have not been conducted with Alpha<sub>1</sub>-Proteinase Inhibitor (Human), Zemaira<sup>®</sup>. It is also not known whether Zemaira<sup>®</sup> can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Zemaira<sup>®</sup> should be given to a pregnant woman only if clearly needed.

Nursing Mothers – It is not known whether Zemaira® is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Zemaira® is administered to a nursing woman.

Pediatric Use – Safety and effectiveness in the pediatric population have not been established. Geriatric Use – Clinical studies of Zemaira® did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. As for all patients, dosing for geriatric patients should be appropriate to their overall situation.

#### ADVERSE REACTIONS

Intravenous administration of Zemaira<sup>®</sup>, 60 mg/kg weekly, has been shown to be generally well tolerated. In clinical studies, the following treatment-related adverse reactions were reported: asthenia, injection site pain, dizziness, headache, paresthesia, and pruritus. Each of these related adverse events was observed in 1 of 89 subjects (1%). The adverse reactions were mild.

Should evidence of an acute hypersensitivity reaction be observed, the infusion should be stopped promptly and appropriate countermeasures and supportive therapy should be administered. Table 3 summarizes the adverse event data obtained with single and multiple doses during clinical trials with Zemaira® and Prolastin®. No clinically significant differences were detected between the two treatment groups.

Table 3: Summary of Adverse Events			
	Zemaira®	Prolastin®	
No. of subjects treated	89	32	
No. of subjects with adverse events regardless of causality (%)	69 (78%)	20 (63%)	
No. of subjects with related adverse events (%)	5 (6%)	4 (13%)	
No. of subjects with related serious adverse events	0	0	
No. of infusions	1296	160	
No. of adverse events regardless of causality (rates per infusion)	298 (0.230)	83 (0.519)	
No. of related adverse events (rates per infusion)	6 (0.005)	5 (0.031)	

The frequencies of adverse events per infusion that were  $\geq 0.4\%$  in Zemaira<sup>®</sup>-treated subjects, regardless of causality, were: headache (33 events per 1296 infusions, 2.5%), upper respiratory infection (1.6%), sinusitis (1.5%), injection site hemorrhage (0.9%), sore throat (0.9%), bronchitis (0.8%), asthenia (0.6%), fever (0.6%), pain (0.5%), rhinitis (0.5%), bronchospasm (0.5%), chest pain (0.5%), increased cough (0.4%), rash (0.4%), and infection (0.4%).

The following adverse events, regardless of causality, occurred at a rate of 0.2% to <0.4% per infusion: abdominal pain, diarrhea, dizziness, ecchymosis, myalgia, pruritus, vasodilation, accidental injury, back pain, dyspepsia, dyspnea, hemorrhage, injection site reaction, lung disorder, migraine, nausea, and paresthesia.

Diffuse interstitial lung disease was noted on a routine chest x-ray of one subject at Week 24. Causality could not be determined.

In a retrospective analysis, during the 10-week blinded portion of the 24-week clinical study, 6 subjects (20%) of the 30 treated with Zemaira<sup>®</sup> had a total of 7 exacerbations of their chronic obstructive pulmonary disease (COPD). Nine subjects (64%) of the 14 treated with Prolastin<sup>®</sup> had a total of 11 exacerbations of their COPD. The observed difference between groups was 44% (95% confidence interval from 8% to 70%). Over the entire 24-week treatment period, of the 30 subjects in the Zemaira<sup>®</sup> treatment group, 7 subjects (23%) had a total of 11 exacerbations of their COPD.

#### HOW SUPPLIED

Zernaira® is supplied in a single use vial containing the labeled amount of functionally active A<sub>1</sub>-PI, as stated on the label. Each product package (NDC 0053-7201-02) contains one single use vial of Zemaira®, one 20 mL vial of Sterile Water for Injection, USP (diluent), and one vented transfer device.

#### STORAGE

When stored up to 25°C (77°F), Zemaira® is stable for the period indicated by the expiration date on its label. Avoid freezing which may damage container for the diluent.

Prolastin<sup>®</sup> is a registered trademark of Bayer Corporation.

Adapted from 19131-04 Revised: March 2006

### **ZLB Behring**



For adults with Alpha-1 antitrypsin deficiency

### Zemaira® — The next generation in purity for Alpha-1 augmentation therapy

- Pure The only Alpha-1 augmentation therapy approved by the FDA as highly purified (lot release specification, >94% purity)\*<sup>,1-3</sup>
- Effective Three times fewer COPD exacerbations than with Prolastin<sup>®†</sup>
- Well tolerated Six times fewer infusion-related adverse events than with Prolastin®\*
- Fast Half or less the infusion time of other augmentation therapies<sup>§,1-3</sup>

Zemaira<sup>®</sup> is indicated for chronic augmentation and maintenance therapy for adults with  $alpha_1$ -proteinase inhibitor (A<sub>1</sub>-PI) deficiency and emphysema.

Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira® are not available.

As with other Alpha-1 therapies, Zemaira<sup>®</sup> may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to  $A_1$ -PI products or their components and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse events were reported in 1% of subjects: asthenia, injection-site pain, dizziness, headache, paresthesia, and pruritus.

Zemaira<sup>®</sup> is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

For more information, call 1-866-ZEMAIRA (1-866-936-2472), or visit www.Zemaira.com.



### Please see brief summary of full prescribing information on following page.

- \* Shelf life purity specification is  $\geq$ 90%
- † In a retrospective analysis in the pivotal clinical trial, Zemaira® patients were three times less likely to experience exacerbations of their COPD than Prolastin® patients
- ‡ No clinically significant differences were detected between the treatment groups
- § Based on recommended dosage as stated in the product package inserts of 60 mg/kg body weight at the infusion rate of 0.08 mL/kg/min
- Prolastin is a registered trademark of Talecris Biotherapeutics, Inc.